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A consortium consisting of 8 partners from 6 
different countries was assembled to carry 
out TARGET project. The consortium 
brought together public bodies and research 
institutes and stimulated a mutual learning 
process where members combined their 
knowledge and carried out research which 
provided a strong and realistic base for 
decision-making in science and policy.  
 
Executive Summary 
The TARGET project’s objective is to design and develop a set of guidelines & recommendations, 
cumulating in a Toolkit, for creating and executing policies to develop the life science/biomed sector. 
The TARGET policy Toolkit, presented in chapter II, is based on the Evolutionary Life Cycle 
approach to innovation, modified to suit the 
challenges and realities facing life science 
industries. The Toolkit is also a first step in 
creating a policy approach applicable to other 
emerging and innovative sectors. The main 
challenge of TARGET project was to translate the 
consortium’s insights on life science/biomed 
innovation into a policy Toolkit that is clear and 
concise, without being overly simplistic or 
advocating misleading ‚cut and paste‛ approaches 
to innovation policy. 
Over the three past decades, the use of cellular and molecular processes to develop new technologies, 
products and services has resulted applications in a number of industries. While the structure of 
these industries is changing, expectations for economic growth remain strong, with major 
implications for innovation policy. Similar to other areas of the knowledge-based economy, 
competitiveness in sectors related to life sciences - at both a regional and national level - seems 
increasingly dependent on the ability to generate new ideas and use them to innovate.  This entails 
the continuous renewal of capability endowments, raising demands for the endorsement of 
interactive learning, networking, foresighting, and the mobilization of complementary knowledges to 
respond to new challenges and opportunities.  
A similar process is characterized by a remarkable and often unmanageable degree of uncertainty 
and complexity. Complexity relates to the plurality of techno-scientific knowledges that need to be 
mobilized as well as the variety of societal, ethical and regulatory factors that must be considered 
when placing new products and services into markets. Uncertainty relates to the low probability of 
success that characterizes research and development efforts, the often very long terms of 
development and the very high investments required to complete it (biological drug development is 
considered as a classical example of such challenges).  
Deployment and transformation over time of dynamic capabilities are the result of an historic and 
context-dependent process, where context-dependency may be seen through the lenses of regional 
and/or sectorial systems of innovation. Accordingly, innovation policy is increasingly refraining from 
linear thinking. Nevertheless, the private sector’s reluctance and/or inability to invest in high risk 
research, and sometimes development, is often described as a classical case of market failure, and 
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prompts public investment in not only basic research but also in the support of industrial 
applications and entrepreneurial exploitation of bioscience. 
Frequently, such investments are explicitly aimed at the emergence of biotech sectoral systems of 
innovation (BSSIs) or bio-clusters. Understanding the main scientific, technological, economic and 
institutional drivers of the emergence and growth of such forms of industrial organization is a 
necessary but insufficient condition to develop appropriate and effective policies. Indeed, mostly 
because of uncertainty and complexity, assessing the actual/potential impacts of such policies and 
providing advice to policy-makers becomes extremely difficult.  
To begin with, any analytical effort and resulting policy recommendation are intrinsically related to 
the institutional and structural features of the local system of innovation. From a top-down 
perspective, it is often assumed that changing the institutional configuration of the system or 
changing the functioning of some of its components – for instance by providing new types of 
incentives to certain agents - will solve market/systemic failures. In turn, this will improve the overall 
performance of the system. Such belief is often reinforced by the study of well-functioning systems, 
whose routines and structures are seen as replicable across space, time and (less frequently) 
industrial sectors.   
Secondly, while the analysis often concentrates on the setting of relevant players, system components 
or assets and institutional features, less attention is paid to the roles played by actors (some of whom 
may not be local) and institutions and the emergent links among them. An initial problem relates to 
the assessment of national/regional endowments, which can lead to flawed conclusions to the point 
where almost every region/state/country of the world has great bioscience, unexploited 
entrepreneurial capacity or the right set of pre-conditions to attract risk capital. 
Thirdly, beside the assessment of the key characteristics of the local environment, understanding 
functions and relationships entails a focus on processes and dynamics. Systems change over time and 
different policies are often required to support and promote emergence and growth at different 
points in time. As noted earlier, this process is often sparked by the unpredicted and unpredictable 
convergence of different types of knowledge and technologies. Finally, it is frequently assumed that 
any type of policy can be implemented provided that a sound rationale exists. In practice, even 
policies with sound rationale may not be implementable because of radical uncertainty, political 
impediments (e.g. lack of long-term commitment) and/or complicated (e.g. multi-layered) governance 
structures. 
Aims and Challenges 
Given such difficulties, the TARGET project sets out to design and develop a structured and 
valorized set of guidelines and recommendations, cumulating into a policy Toolkit, for targeted R&D 
policies that focus on the biomedical sector to promote the emergence of BSSIs/bio-clusters. In line 
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The TARGET approach provides policymakers with 
a conceptual framework that will be productive for 
policymaking and policy implementation. By 
analytically breaking the policy challenge into 
different elements it becomes easier to understand 
what has to be addressed and how. The three 
elements of TARGET Approach are: Industry Life-
Cycle; Sector Drivers; and Policy Dimensions.  
 
with the overall OMC-NET objectives,1 the purpose of the Toolkit is to provide structured guidance 
and instructions as to how to create, enhance, improve and nurture targeted policies and to enable 
concrete policy-making decisions. 
The proposed Toolkit was developed by identifying key systemic drivers and policy capabilities 
required in order to formulate and implement successful targeted R&D policies. This includes the 
ability to define strategic priorities, to evaluate technological gaps in prioritized areas, to identify 
elements within the national/regional innovation system responsible for achieving the selected 
priorities (including the missing elements), to identify potential system failures, to formulate effective 
policy and to ensure coordination between the relevant policymakers and government agencies. 
Targeting is seen as an instrument for coping with global competition. The ability to design targeted 
R&D policies successfully is associated with the ability of policymakers to identify not only basic 
market failure, which result in the formulation of R&D support schemes, but also coordination 
failures which may block or impede the growth of the targeted business sector.  
The Structure of TARGET Approach 
The TARGET Toolkit is meant to provide policymakers with a systemic way of addressing the 
challenge of supporting the emergence of bio-clusters. Working in a volatile global environment, 
policymakers are faced with conditions of 
high uncertainty. Within this context, it 
becomes very challenging to assess the 
effect of policy measures on different parts 
of the innovation system; thus, a systemic 
way of addressing this issue becomes highly 
relevant. The focus is on the biomedical 
sector that presents the highest level of 
complexity/uncertainty management. 
Element 1: Industry Life-Cycle 
The Industry Life-Cycle deals with the development of the biotech sector itself. The TARGET 
approach recognizes that different industries progress through a cycle of development which is 
uniquely characteristic to them. In addition, in line with Avnimelech and Teubal (2006) we tested the 
hypothesis that bio-clusters follow a similar cyclical development, one that is based upon an 
idiosyncratic set of background conditions. Then, three phases of development have been recognized 
to date: Background Phase, Pre-Emergence Phase and Emergence Phase. Different phases call for 
different policy measures and its imperative that policymakers identify what phase they are about to 
interact with. Thus, the very first element of the TARGET approach deals with the identification of 
the current phase of the sector in terms of the Industry's Life-Cycle. This is done through the Sector 
                                                          
1
 http://ec.europa.eu/invest-in-research/coordination/coordination02_en.htm 
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Drivers. Once the phase has been recognized, all stakeholders can focus on advancing the sector to 
the next cycle. 
Element 2: Sector Drivers 
The Sector Drivers are key functional elements of the sectoral systems of innovation that constitute 
the real ‘engines’ which move the sector from one phase of the Life-Cycle to the next one. Studying 
different case studies around the world, we have identified the following Drivers: Science, Training, 
Commercial, Financial, Human Resources and Other Institutions. For example, at the Background 
Phase there are no specific capabilities in biotechnology, but there are established capabilities in 
general purpose R&D. Therefore, the Science Driver will look differently at this phase in comparison 
to the Pre-Emergence Phase, in which specialization in biotechnology begins. Understanding which 
of the Drivers is lagging behind helps policymakers determine what the best entry-point is in terms 
of policy measures. 
Element 3: Policy Dimensions 
The Policy Dimensions deal with the different decisions that must be taken at any point of the policy 
process. These dimensions describe how to approach a Driver. Some Policy Dimensions, such as the 
decisions on the Vision and Assessment, must be present all through the policy process (and will be 
termed strategic decisions), while others change with every policy modification (and are thus termed 
tactical decisions). Supporting a biotechnology sector takes time and the policy process will go 
through different stages. At each stage there is a need to define the relevant Policy Dimensions and to 
decide on each one.  
 
The Toolkit’s Calibration Process: Case Studies and Policy Dimensions 
In this phase, the trajectories of emergence of a number of already emerged bio-clusters were 
carefully reconstructed and examined. The main objective was to find out whether our approach was 
fit enough to (1) reconstruct such process of emergence from an historical prospective, (2) reveal 
cumulative and co-evolutionary processes between any of the abovementioned drivers and/or crucial 
network dynamics within the local/sectoral system (3) detect policy interventions that stimulated (or 
hindered) the process of emergence (including an initial setting of strategic priorities). 
 
 
 
 
 
 
Scotland 
The Scottish pursuit of biotechnology began 
in the mid-nineties with its strong academic 
capacity in biomedical research and the belief 
amongst policymakers that biotechnology 
would be a future growth-generating 
industry. The strategy developed and then 
executed by Scottish Enterprise under the 
'Framework for Action' aimed at bringing  
 
Singapore 
Singapore’s effort at creating a bioscience 
cluster was completely orchestrated by the 
government. Following successful 
government-led economic development 
campaigns in the 1970s and 1980s, the 
Singaporean government decided to pursue 
the emergence of a knowledge-based 
economy, with bioscience as one of its pillars. 
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academic work to the market, and starting 
new firms across various bioscience-related 
activities 
The pre-emergence phase (1999-2003) saw the 
Framework for Action successfully meeting 
its numerical targets of job creation and 
employment numbers. Policy efforts 
continued through established programs, but 
as the sector grew and industry became more 
influential, the strategic emphasis began to 
change to one of growing existing firms 
rather than continuing to seed more new 
firms.  
The Scottish system peaked in 2003 in term of 
its growth, but suffered a setback with the 
failure of a number of therapeutic firms – 
these firms had enjoyed success in their IPOs, 
but suffered failures of their products in 
trials. The result was a loss of investment 
from outside Scotland, and a retrenchment of 
local efforts towards less risky areas of the life 
sciences such as medical devices and 
diagnostics.  
 
The official decision to pursue bioscience was 
made in 1999; however there had been some 
previous activity in this direction in the 1980s 
and 1990s. Singapore’s capabilities in 
electronics attracted Big Pharma to establish 
manufacturing facilities in Singapore. The 
targeting process began under 'the Science 
and Technology Plan 2005' and the 
Biomedical Initiative (BMI), pushing the 
country from Background Conditions to Pre-
Emergence.  
Capabilities had to be imported and thus, 
tremendous incentives were given to star 
scientists from abroad to relocate to 
Singapore. New dedicated research institutes 
were established and international scientists 
were given managerial positions. The initial 
goal was to create R&D experience and train 
local PhDs. Start-ups were founded with 
public money but were soon privatized. The 
next strategic phase began after 2005, with an 
emphasis on translational medicine and the 
creation of greater network connections 
between actors in the local cluster. 
 
Israel  
The development of the Israeli biotech cluster 
can be attributed to the very strong science 
base as well as to high level of 
entrepreneurship. The latter is partly due to 
the success of the high tech-sector which was 
followed by VCs, IP services, links to 
networks, etc. This progress also signalled to 
the scientific community that entrepreneurial 
activity was a possibility for career building. 
 
Medicon Valley 
Arguably one of the few European examples 
of strong fully-fledged biotech cluster, 
Medicon Valley is located in the cross-border 
region of Øresund and it can be considered as 
an example of the joint vision of the Danish 
and Swedish governments to create Europe’s 
pre-eminent hub for life-sciences R&D and 
production. An Øresund Committee was 
created in 1993 as a forum for voluntary  
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Initiating and supporting this mission was characterized by strong collaboration between the 
business sector, government and academic institutions. In 1959, NC established the research 
triangle park (RTP). The process was coordinated and involved all major players. In the early 
1980s RTP was already a success story; this provided NC the confidence that it could pull-off a 
coordinated strategic process. The North Carolina Board of Science and Technology (NCBST) 
was established in 1963 by North Carolina General Assembly to encourage, promote, and 
support scientific, engineering, and industrial research applications. In the early 1980s the 
government platform for targeting was already effective and stable.  
Since the mid-late 1990, the biotechnology sector started to grow rapidly. Also, because of 
changing global trends in the bio value-chain, in 2000, NCBST reassessed the key needs and 
opportunities for continued emergence. In addition, the CRO and CMO sub sectors were 
growing fast, with the Bioprocess Manufacturing sector as the new focus. The slow-down in the 
market in the early millennium stalled NC’s emergence, but a second attempt was launched, 
keeping some of the same foci but also including expansion in agro-tech, bio-fuels and medical 
devices.  
 
During and prior to the background phase 
Israel had invested massively in building a 
strong academic science base, with good 
results in the life sciences. The pre-emergence 
phase showed good progress on the medical 
device sector with some very successful IPOs 
and M&As.  
However, the failures of some phase IIIs had 
a negative influence on the willingness of VCs 
to further invest in drug development 
companies. This phenomenon caused the 
Government to establish a $400 million 
public\private VC funds which will be 
dedicated to biotech. Currently, Israel is 
"stuck" at the pre-emergence phase with no 
real support system to take into the next 
phase.  
 
political cooperation for the region. The 
Committee decided to focus on biotechnology 
due to its potential, and to piggyback on the 
Medicon Valley project, initiated in 1995 by 
Lund and Copenhagen Universities to 
stimulate the formation of a cross-border 
bioregion. 
The main elements that allow to identifying a 
phase of emergence (early 2000) were the 
high growth of venture capital market, both 
from the supply and demand side. Moreover, 
other indicators, such the creation of start-
ups, gazelle firms, the drug development 
pipeline, IPOs or international alliances show 
a positive and dynamic co-evolution of the 
elements that form this cluster. Furthermore, 
new biotech programs have been 
implemented to strengthening human 
resources and support entrepreneurship and 
commercialization. 
 
North-Carolina 
Since the mid 1950s developing a knowledge  - intensive economy was a strategic priority of NC.   
TARGETED R&D POLICY 
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The Toolkit’s Testing Process: Policy Analysis 
At this stage, the framework was tested in the context of four European Partner Countries/Regions 
(France, Galicia, Slovenia and Lithuania) as well as in Israel. The exercise led to a stimulating 
learning process, which in some cases resulted in significant and direct changes in policy action. In 
spite of the heterogeneity of BSSIs (in terms of both emerging and structural features) and systems of 
governance examined, most policymakers recognized the utility of thinking in terms of cycles and 
development phases. 
With a basic understanding of the Extended Industry Life-Cycle and the Sector Drivers which move 
the biotechnology sector from one phase to the next and how policy-making was able to support (or 
hinder) the process of emergence of local bio-clusters, our analysis concentrated on the location of the 
bio-cluster within a defined phase of development, with a view to understand the current structural 
and dynamic features of each local system. As noted earlier, this is no easy task as each BSSI 
presented a much greater degree of complexity than traditionally defined industrial sectors. 
This allowed the identification of an initial set of dimensions which are seen as strategic because they 
establish the call to pursue a BSSI/bio-cluster actively and the broad vision that efforts will work 
towards achieving. Depending on the stage of development of the local systems, the focus can be on 
either the assessment of background/pre-emergence conditions or the recognition of key co-
evolutionary processes involving the drivers of bio-cluster emergence. Once these high level 
decisions are made, the specific steps needed to fulfill them will have to be carried out, i.e. the tactical 
decisions and steps.  
Concerning background/pre-emergence conditions, our analysis laid special emphasis on the 
essential role of the bio-scientific base (more as a source of required skills than as exploitable 
intellectual property), some key aspects associated with the existence of an entrepreneurial culture 
(such as acceptance of risk and failure), ability to achieve political consensus, and ability to develop 
strong leadership (preferably in the form of body of experts able to advise on strategic planning and 
sufficiently detached from political influences to ensure consistency overtime).  
In terms of cumulative dynamics, a series of policy challenges stretching across countries/regions 
were identified. They concerned not only the need to increase availability of public and private 
finances and support local start-ups (many development agencies around Europe have devoted 
significant investments to ‘closing financial gaps’, with results frequently below expectations), but 
also: (1) meeting demand for both technical and managerial skills in a timely manner; (2) investing in 
both soft and physical infrastructure; (3) when feasible, combining local experiences, skills and 
resources with international partners in order to grow (a number of) local firms into sizable 
businesses with an international reach; and (4) promoting learning processes that directly involve 
policy-makers. 
TARGETED R&D POLICY 
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The tactical decisions discussed will likely be carried out by policymakers ‘on the ground’ trying to 
match their actions to the vision they have been charged with working towards. This tactical level of 
our analysis is explicitly related to the following dimensions: (a) the identification of key stakeholders 
and (b) entry-points for policy implementation, (c) effective policy design and (d) efficient policy 
evaluation. Regarding these dimensions, the testing process allowed for the learning of a number of 
key lessons. 
Important Lessons 
While the phases and the drivers within each phase can be generally described, cases’ qualities in 
each phase and their transition through each phase can vary quite widely. However, based on the 
case studies and discussions with policy experts, some generalized lessons are presented here. These 
constitute warnings and major guide posts for policymakers following the Target approach. 
 
 
(a) The evolutionary development of biotech sector is long. A main lesson to be taken from the 
various case experiences is that developing a BSSI/bio-cluster requires long timelines of more than 
20 years, particularly if starting from a background phase where elements such as an industrial 
base or commercial experience are missing. This means that the incentives for investors to enter the 
arena are few, the virtuous cycles of activity become more difficult to create, and most efforts will 
have to be concentrated on transforming scientific knowledge into commercial use. Without a 
scientific base, this becomes an even larger challenge with longer timelines. Before pursuing a 
Targeted policy of biotechnology, a realistic assessment of capabilities and commitment is crucial. 
 
 
(b) The existence of excellent scientific research is a key precondition for the development of a 
complete cluster, due to the importance of the scientific knowledge in the development of this 
sector. Strength in general research and training infrastructure at this stage means that the focus 
can be on utilizing the knowledge base rather than having to build it up before pushing the 
strategy’s vision. In biotechnology, high quality research is a key success factor; it should be 
argued that top quality research is a key factor of success. However, it should also be noted that 
there have been relatively successful biotechnology firms based on less-than-revolutionary science, 
which highlight the importance of industry applicable science.  
(c)  Strengthening a science base in pursuit of industry targets is different from targeting a science 
base for the sake of having the best academic science. In many cases, a strong science basis results 
in a capable workforce rather than a series of entrepreneurial ventures spurring out of it. 
 
Timelines and Commitment 
 
Science and Research 
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(d) Excellent science in conjunction with financial support for R&D and the availability of VC 
funds are the basic elements in the development of a biotech sector. 
(e)  At early stages of a biotechnology sector’s development, when excellent science is not well 
established and there is no biotech industry in place, looking to finance policy and the 
establishment of start-ups as an entry-point is questionable.  
 
 
(f)  A strong leader can move forward the development of a biotechnology sector by acting as an 
advocate for the sector and drawing together various interests and stakeholders to cooperate in the 
pursuit of biotechnology. This leadership of individuals is then normally translated to an 
organization(s), referred to as a Body of Knowledge in the Toolkit (chapter II), which takes these 
ambitions forward in practical terms. Successful a Bodies of Knowledge are arm’s-length, pro-
active, forward-looking bodies able to operationalize the strategic vision. 
(g) According to focus group comments, without a Body of Knowledge, the success of a Target 
policy developing a biotechnology sector is highly unlikely. A Body of Knowledge can be a person, 
an unofficial governance group, or an official body given arm’s-length authority to conduct 
foresight and recommend/implement policy. An important point made, however, was that the a 
Body of Knowledge  had to be able to ask the hard questions and make the difficult decisions 
which may not necessarily appeal to short term political interests. Without this ability, the 
difficulty of actively pursuing a biotechnology sector increased. 
 
 
(h) The buy in of major players in business, government and academia will help the policy process 
navigate the complexities of establishing a biotechnology sector. For example, the North Carolina 
targeting policy benefited from a comprehensive assessment, full-support of the government and 
an explicit decision to target biotechnology. The creation of the North Carolina a Body of 
Knowledge resulted in an independent focal-point for strategic thinking, policy design, and 
implementation coordination. The structure of the Body of Knowledge meant that it was able to 
offer arm’s length, unbiased evaluation and policy design.  
(i)   Broad political consensus is required to implement an effective biotechnology policy. Failing to 
reach consensus among the stakeholders and coordinate their action may slow dramatically the 
development of the cluster.  For example, targeting becomes much more complex when a public 
entity responsible for one aspect of the innovation process is not coordinated with other entities 
responsible for other parts of the process, a power differential, and a lack of consensus.   
Basic Drivers for Biotechnology 
 
Strategic Leadership 
 
Political Consensus and Realistic Assessments  
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The effect of leadership change at the strategic institutional level and at tactical organizational 
levels can be significant. Changes in leadership may bring about changes in goals, priorities and 
expectations of a political or ideological nature and may therefore impact the subsequent policy 
measures and assessment criteria used in building a cluster. While change may be necessary 
during the long-term implementation of a strategy, changing the strategic vision should be based 
on regular assessments and evaluations rather than political preferences and short-term reactions. 
(j)   Many times the ‚ambition to bio‛ initially expressed by leaders may be too optimistic or 
ambitious for the country/region’s capacities or resources. This may be because of uninformed 
expectations, or the desire to emulate ‚successful‛ cases.  In this case the importance of realistic 
system assessments becomes apparent. A successful Target strategy does not have to be equivalent 
to the achievement of a full-fledged, biotechnology cluster that covers a variety of products and 
services. A Target strategy may aim to achieve success in niche markets, the creation of SMEs, or a 
more modest participation in the biotechnology value chain; the adequacy of the goals will 
correspond to what stage of development the region or country finds itself in terms of its scientific 
and commercial resources and experience. 
  
 
(k) As mentioned above, biotechnology is a very risky business; failure must therefore be an 
accepted part of the process and seen as a source of experience. While the goal is to minimize 
failure, it should be acknowledged that all of the successful cases of sector development have 
involved learning through experience, which includes failure. Completely removing support or 
resources from an industry as a result of a first round of failures may be pre-mature and should be 
done only after careful systemic analysis.  
(l)   Decisive policy after a failure during the targeting process may have positive effects in 
creating momentum and confidence. Lack of success in some areas may also be the catalyst for the 
discovery of new niches or opportunities in other areas.  
 
 
(m) Because of the importance given to system assessment and policy evaluation in the Target 
Toolkit, qualitative and quantitative indicators must be carefully considered and selected – and 
they must fit the goals of the strategy and policies being implemented. It is dangerous to use 
indicators as a general check list of progress without understanding why they were selected and 
how they can feed back into Target efforts. 
Changing indicators mid-stream create problems of comparison to previous years, and will likely 
show a negative performance from policy measures initially planned with different performance 
Acceptance of Failure, Need for Adaptability 
 
Indicators and Metrics 
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milestones in mind. This is not to say that change in indicators should not occur if it is justified, 
however, it is important to bear in mind potential consequences. 
(n) Evaluation of policies demonstrates commitment to achieve results and improve policies. It 
can also be used as a mechanism of transparency which is attractive to investors and commercial 
interests.   
 
 
(o) Successful measures to increase entrepreneurial activity generally involve lowering the cost of 
engaging in entrepreneurial activity. However, in some key areas such as drug development and 
diagnostics, this may not be possible as because of the increasing stringency of the regulatory 
frameworks (safety/efficacy of new drugs/diagnostic tools). 
(p) Economic downturns may have negative effects on otherwise well-functioning sectors by 
constricting the availability of capital, as well as potentially the demand for products. The 
strengths of the sector must therefore be recognized through consistent evaluations, and some key 
policies to help develop the sector should be flexible enough (and effective in lowering the cost of 
entrepreneurial activity) to deal with this uncertainty (e.g. R&D tax credits). In areas characterized 
by high capital requirements and uncertainty (drug development) this may require a radical 
rethink of the strategy’s objectives. 
 
  
Sustainable Policy Initiatives and Economic Downturns 
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I. On Biotechnology, Life Sciences and 
Biomedicine 
Biotechnology, life sciences and biomedicine are close concepts with no clear boundaries. Its 
conceptualization varies depending on the authors, the context of usage or the specific purpose. 
Biotechnology is a complex and interdisciplinary field experiencing rapid changes in the 
knowledge base and its applications. Borders between life sciences and biotechnology are moving 
due the new developments and the cross fertilization among the different areas and techniques. 
Biotechnology draws on basic biological sciences like genetic, molecular biology, cell biology, 
microbiology or biochemistry and makes an increasing usage of methods and techniques from other 
areas like information technology, nanotechnology, robotics or chemical engineering. 
These interactions and diffuse borders are clear at the scientific level but particularly notable in the 
productive sector. There are companies whose activity can be categorised within more than one 
sector. In fact, the penetration of biotechnology is increasingly widespread and diffuse. This not only 
shows its potential application to numerous fields, but also the difficulty in delimiting concepts such 
as biotechnology, biosciences, life sciences, medical technologies, health sciences, medical devices and 
biopharma.  
In order to clarify the main areas and applications included in the broad definition of biotechnology, 
we refer to the most consensual definition provided by the OECD. Box 1 includes the definition used 
by the OECD. 
 
 
 
 
 
 
 
 
 
 
Box 1: Definition of Biotechnology 
According to the OECD, Biotechnology is the application of science and technology to living 
organisms, as well as parts, products and models thereof, to alter living or non-living materials 
for the production of knowledge, goods and services.  
This single definition not only covers all modern biotechnology, but also many traditional or 
borderline activities that have been used for a very long period of time. Modern biotechnology is 
defined as the use of cellular, molecular and genetic processes in the production of goods and 
services. It is associated with a different set of technologies including the industrial use of 
recombinant DNA, cell fusion, tissue engineering and others. Traditional biotechnology refers 
mainly to fermentation and plant and animal hybridization. The modern and traditional 
biotechnologies can be used in combination which is considered as modern biotechnology. 
Source: OECD, 2005 
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The OECD displayed an indicative list of biotechnology techniques (see Box 2). This is the list 
commonly included in EC studies and reports. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sometimes biotechnology is classified also according to its applications. The most usual applications 
are related to health, agriculture, environment, industry and sea. Following this criteria the 
biotechnology sector is occasionally described as a rainbow (see figure 1), with each subsector having 
its own color, see figure 1. 
 
 
 
 
Box 2: List of Biotechnology Techniques 
 DNA/RNA: Genomics, pharmacogenomics, gene probes, genetic engineering, DNA/RNA 
sequencing/synthesis/amplification, gene expression profiling, and use of antisense 
technology. 
 Proteins and other molecules: Sequencing/synthesis/engineering of proteins and peptides 
(including large molecule hormones); improved delivery methods for large molecule drugs; 
proteomics, protein isolation and purification, signaling, identification of cell receptors. 
 Cell and tissue culture and engineering: Cell/tissue culture, tissue engineering (including 
tissue scaffolds and biomedical engineering), cellular fusion, vaccine/immune stimulants, 
embryo manipulation. 
 Process biotechnology techniques: Fermentation using bioreactors, bioprocessing, 
bioleaching, biopulping, biobleaching, biodesulphurisation, bioremediation, biofiltration and 
phytoremediation. 
 Gene and RNA vectors: Gene therapy and viral vectors. 
 Bioinformatics: Construction of databases on genomes, protein sequences; modeling complex 
biological processes, including systems biology. 
 Nanobiotechnology: Applies the tools and processes of nano/microfabrication to build 
devices for studying biosystems and applications in drug delivery, diagnostics etc. 
Source: OECD, 2009. 
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Figure 1: The Biotechnology Rainbow 
 
Source: Medicon Valley Alliance 
 
red biotech is focused on 
health and application to the 
medical sector; white 
biotech (sometimes known as 
grey biotech) refers to 
applications production 
process of the industrial sector; 
green biotech refers to 
agricultural, plants and 
environmental applications of 
biotechnology; and blue 
biotech refers to the marine-
based biotech and marine 
applications2.  
 
Life sciences is a broader concept than biotechnology including all scientific areas dealing with 
biology, medicine, veterinary, biochemistry and pharmacy, making use of all traditional and modern 
methods and technologies. Thus, biotechnology is a subset of life sciences based on specific 
techniques. The life sciences sector includes pharmaceutical, biotechnology and medical technology 
activities. Here are included both the new biomed sciences and the more traditional medical and 
pharmaceutical fields.  
   
 Pharma and Biopharma: drug discovery and development, drug delivery, biotech medical 
technology, diagnostics and drug production. 
 Biotech: Tools and supplies, bio-production, agricultural biotechnology, industrial and 
environmental biotechnology and food-related biotechnology. 
 Medtech: Healthcare equipment, active and non-active implantable devices, 
anaesthetic/respiratory equipment, dental devices, audiologic devices and hearing aids, 
electromedical and imaging equipment, ophthalmic devices, surgical instruments and supplies 
for electromedical and imaging applications, medical disposables, contract research 
organisations (med tech) and IT & training. 
 
Biomedicine can take two different meanings: traditional and modern interpretations. In the 
traditional sense, biomedicine is a medical science based on the application of biological and other 
natural-science principles to clinical practice. This "traditional science" includes fields such as 
medicine, veterinary, odontology and other biosciences (biochemistry, chemistry, biology, histology, 
                                                          
2 Other colours used are yellow (Food Biotechnology, Nutrition Science); brown (Arid Zone and Desert Biotechnology); 
purple: Social and legal aspects (Patents, Publications, Inventions, IPRs); gold (Bioinformatics, Nanobiotechnology); grey 
(Classical Fermentation and Bioprocess Technology) and black (Bioterrorism). 
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genetics, anatomy, physiology, pathology, biomedical engineering, zoology, botany and 
microbiology). In the modern sense, biomedicinemakes intensive use of knowledge, methods and 
techniques developed through biotechnology and is therefore is closely related to red biotech (see box 
2 below). 
 
Biotechnology and Life Sciences companies 
Biotechnology and life science sectors are clearly science-based activities. However, there are biomed 
companies which are not science/R&D intensive on a large extent. In addition, even among the 
scienc-extensive companies, usage of biotech knowledge or biotech techniques is not necessarily part 
of all these companies' activities.  According to the OECD, a biotechnology firm can be defined as a 
firm that is engaged in biotechnology by using at least one biotechnology technique to produce 
goods or services and/or to perform biotechnology R&D. Some of these firms may be large, with 
only a small share of total economic activity attributable to biotechnology. 
The life science companies include pharmaceutical, biotechnology and medical technology activities 
(Medtech). The characteristics of companies in the medical technology sector are the development of 
medical products which are not drugs. On the other hand, the characteristics of companies in the 
pharmaceutical sector are the development of drugs and various kinds of therapeutic products or 
methods.  
The biotechnology sector is characterised by companies developing applications of science and 
technology to living organisms as well as parts, products and models and altering living or non-
living materials for the production of knowledge, goods and services.  
Together, these three sectors (Biotechnology, Pharmaceutical and Medtech) constitute what is known 
as the life science industry. Due to the overlapping nature of the section's definitions, there are 
companies whose activity can be categorised as belonging to more than one sector. For instance, 
companies involved in drug discovery could be defined neither as exclusively pharmaceutical nor as 
exclusively biotechnology companies. Therefore, each company has been classified into one specific 
business segment, whereas an individual company can be found in more than one sector. 
 
 
 
 
 
 
 
 
Medtech Biotechnology 
Pharmaceutical 
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Subsector Main sector Main sector Main sector 
Drug discovery/development Pharma Biotech - 
Drug delivery Pharma Biotech - 
Drug production (not biotech) Pharma - - 
In vitro diagnostics Biotech Medtech - 
Biotech medical technology Biotech Medtech - 
CRO Pharma Biotech Medtech 
Bioproduction (healthcare related) Biotech Pharma - 
Biotech tools and supplies Biotech - - 
Agrobiotechnology Biotech - - 
Environmental biotechnology Biotech - - 
Food related biotechnology Biotech - - 
Industrial biotechnology Biotech - - 
Implantable devices (active and non-active) Medtech - - 
Anaesthetic/respiratory devices Medtech - - 
Electromechanical medical devices Medtech - - 
Radiation devices (diagnostic and therapeutic) Medtech - - 
Ophthalmic/optical products Medtech - - 
Dental devices Medtech - - 
Reusable andsingle-use devices Medtech - - 
Information and communication tools Medtech - - 
Healthcare facility products and adaptations Medtech - - 
Assistive products for disabled people Medtech - - 
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II. A Generalized Toolkit for Policymakers  
1. Introduction to TARGET 
Policymakers have increasingly taken it upon themselves to introduce policies promoting the 
economy’s ability to host science-based industry. Science-based sectors are emphasised as sources of 
economic growth and as potential market-arenas for the enhancement of the national or regional 
economy’s competitiveness. Some policies are responses to market failures, plugging gaps in the 
resources available to firms or the science base while not necessarily seeking to change the systemic 
structures within which these firms operate. As more research on science-based sectors and 
innovation has been conducted, and as experience in the business and policy areas has accumulated, 
arguments for more systemic approaches to policy have increased.  
The TARGET approach presented here will help policymakers form a strategic roadmap and 
determine feasible interventions that lead to a functioning biotechnology system of innovation within 
a country or region. The goal of the Toolkit is not to present a single recipe of specific policies for 
success; as will be noted later on, the variety of cases and their development mean that no single path 
to a functionally biotechnology sector can be realistically described. 
The TARGET approach takes the biotechnology system of innovation as the ‚unit of analysis.‛ By 
taking such a unit of analysis, the approach can account for the different structures which form a part 
of the system and affect its actions, as well as take into account external influences, while not losing 
sight of the sectoral innovation system as the whole unit. Alternatively, what the TARGET approach 
does offer is a way for policymakers to work through this complexity and come up with a tailored, 
context specific strategy based on realistic assessments of their country or region’s resources and 
capacities. 
 
The TARGET approach is based on an evolutionary theory of innovation which sees different sectors 
as going through a life cycle of development. At different stages of a sector’s progress, the ground 
work for development to the next stage is laid and the specifics of this groundwork will influence 
how the subsequent stage is realized. When describing the different Phases of evolution, Sector 
Drivers will be discussed which are key to moving the sector through the phases to maturity. The 
drivers described as necessary to take into consideration for assessment purposes and policy action 
fall under science, training, commercial capacity/experience, finance and human resources. They also 
include ‚other institutions‛ which would include IP, a working health delivery system and different 
regulatory systems which can affect the costs of the biotech sector (e.g. drug regulation, tax regime).  
These categories of drivers will be used when discussing the phases of evolution, however the 
individual drivers and their values/qualities will change phase by phase; these changes should be 
reflected in policy interventions implemented to reach policy goals. 
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2. The Structure of TARGET Approach 
The TARGET Toolkit is meant to provide policymakers with a systemic way of addressing the 
challenge of supporting a biotechnology sector. Working in a volatile global environment, 
policymakers are faced with conditions of high uncertainty. Within this context, it becomes very 
challenging to assess the effect of policy measures on different parts of the innovation system; thus, a 
systemic way of addressing this issue becomes highly relevant. The biotechnology sector is 
dynamically changing both in terms of the way we understand scientific and technologic 
developments and in terms of how policymakers are supporting the emergence of the sector. 
 
The main objective of the TARGET approach it to provide policymakers with a conceptual 
framework that will be productive for policymaking and policy implementation. By analytically 
breaking the policy challenge into different elements it becomes easier to understand what has to be 
addressed and how. The three elements of TARGET Approach are: 1) Industry Life-Cycle; 2)  Sector 
Drivers; and 3) Policy Dimensions.  
 
Element 1: The Industry Life-Cycle 
The Industry Life-Cycle, presented in Chapter 3, deals with the development of the biotechnology 
sector itself. Based on an evolutionary perspective, the TARGET approach recognizes that different 
industries progress through a cycle of 
development which is uniquely 
characteristic to them. In the case of 
biotechnology, three phases of 
development have been recognized to 
date: Background Phase, Pre-
Emergence Phase and Emergence 
Phase. Chapter 3 details each phase's 
properties in terms of the 
biotechnology sector. Different phases 
call for different policy measures and 
its imperative that policymakers 
identify what phase they are about to 
interact with. For instance, at the 
Background Phase there would likely 
be little specific expertise in 
biotechnology within public or private 
R&D, thus the implementation of a grand VC program would not be the best entry-point for policy as 
there would be few opportunities present in the investment pipeline. Thus, the very first element of 
Element 2: Sector Drivers 
Answers the Question: 
What do we need to move forward? 
Element 1: Industry Life-Cycle 
Answers the Question: 
Where are we? 
Element 3: Policy Dimensions 
Answers the Question: 
How to approach what we need? 
The Structure of the Toolkit 
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the TARGET approach deals with the identification of the current phase of the sector in terms of 
the Industry's Life-Cycle. This is done through the Sector Drivers. Once the phase has been 
recognize, all stakeholders can focus on advancing the sector to the next cycle. 
  
Element 2: The Sector Drivers 
The Sector Drivers, detailed in Chapter 4, are the ‘engines’ which move the sector from one phase of 
the Life-Cycle to the next one. Studying different case studies around the world, we have identified 
the following Drivers: Science, Training, Commercial, Financial, Human Resources and Other 
Institutions. Chapter 4 details each Driver at length and its features at every phase of the Life-Cycle. 
Using the example mentioned above, at the Background Phase there are no specific capabilities in 
biotechnology, but there are established R&D capabilities in general. Therefore, the Science Driver 
will look differently at this phase in comparison to the Pre-Emergence Phase, in which specialization 
in biotechnology begins. Understanding which of the Drivers is lagging behind helps 
policymakers determine what the best entry-point is in terms of policy measures. For example, if 
all Drivers are at the Pre-Emergence Phase, but the Finance Driver is lagging, then starting with 
financial support may be the appropriated course of action. Thus, assessing how the country/region is 
doing in terms of each of the drivers allows for policy coordination and clarification of the policy 
challenge. Once the Drivers have been mapped, the Policy Dimensions will help to address the 
specific Drivers requiring attention. 
 
Element 3: The Policy Dimensions 
The Policy Dimensions, detailed in Chapter 5, deal with the different decisions that must be taken at 
any point of the policy process. These dimensions describe how to approach a Driver. Some Policy 
Dimensions, such as the decision on the Vision and Realistic Sectoral Assessment, must be present 
during the entire policy process (and will be termed strategic decisions), while others, such as the 
decision on Entry-Points, change with every policy modification (and will thus be termed tactical 
decisions). Supporting a biotechnology sector takes time and the policy process will go through 
different stages. At each stage there will be a need to define the relevant Policy Dimensions and to 
make the relevant decisions. For instance, the entry-point for the first policy scheme will be different 
from the scheme in the second stage of policy, which might take place some five years after the first. 
Thus, Chapter 5 addresses the issue of actual policy implementation and provides a framework for 
formulating concrete policy programs by listing all areas which require attention.  
TARGET offers conceptual tools that make the challenge of supporting a biotechnology 
sector easier and clearer. Due to the complex nature of the challenge, we do not offer one-
size policy schemes but rather focus on the different elements which policymakers must 
take into consideration while formulating their own particular schemes. The following 
chapters will provide useful information and productive tools.  
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3. The Industry Life-Cycle 
The TARGET approach is based on an evolutionary theory of innovation, The Industry Life Cycle. At 
every stage of the sector’s progress, the ground work for development to the next stage is laid, and 
the specifics of this groundwork will influence how that subsequent stage is realized.  
A biotechnology system is seen by the Industrial Life Cycle Approach as a dynamic, constantly 
evolving set of structures affected by: 
 Spontaneous interactions between agents of knowledge creation and agents of commercialization.  
 The geographic context.  
 The historical context, including industrial and social history. 
 The influence of the political system and agents purposely using policy mechanisms to grow the 
economy and exploit the opportunities presented by new knowledge and technology.  
 
Using this approach allows policymakers to see not 
only how policies may have an impact on a current 
area of the economy, but also how it may impact 
events or conditions in the future, thus, it 
contributes to any long-term industry-building 
goals. 
The industry Life Cycle Approach, which sees different sectors as going through a life cycle of 
development,  breaks down an industry’s levels of development and maturity into three phases:  
The Background Phase is the phase before the sector actually appears. In the 
background phase there is as yet no biotechnology sector per se; rather the initial seed conditions 
are present or being formed. At this stage there would be very little commercial activity or experience 
with the sector, though transferable knowledge, experience and institutional settings should be 
present in order to begin transitioning to the next phase. Furthermore, while actors may have 
rudimentary awareness of the potential for the creation of a biotechnology sector and how the current 
conditions encourage the emergence of the sector, there is as yet no consistent, organized interaction 
between actors in this regard.  
The Pre-Emergence Phase is the phase in which initial activities of the sector appear.  
The pre-emergence phase shows the beginning of a biotechnology sector, though its main feature 
is that the activities are not yet self-sustaining or institutionalized; rather, the activities suggest 
A realistic assessment of commitment 
is crucial, since the development of a 
biotechnology sector requires long 
timelines of more than 20 years.  
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some specialization in the R&D sector, strong science, the development of entrepreneurial action and 
some initial commercial activity and investment. These activities involve some implicit exploration of 
the different market possibilities that the nascent sector may move towards. Actors in this phase 
begin showing an awareness of the sector, and interactions between actors are increasing. 
The Emergence Phase is the phase before the sector becomes standardized. The 
emergence phase shows the sector beginning to achieve critical mass. Commercial exchanges begin 
to lose their one-off, tentative nature. Whereas in the Pre-emergence phase transactions between 
actors may have been exploratory or ad hoc, in the emergence phase these transactions have become 
more regular.  Of course, activity may still be exploratory and structures may be adjusted to facilitate 
what is still a new market with high levels of uncertainty, but biotechnology (or its sub-sectors) does 
not have to ‚prove itself‛ as a commercial activity or source of investment and public policy. 
 
 
 
 
 
Background Pre-Emergence Emergence 
The Industry over Time 
Path of Country A 
Path of Country B 
The Industry Life-Cycle 
Path of industry development from the moment TARGET 
approach begins  
An Important Note on the Idiosyncratic Nature of the Biotechnology Life-Cycle:  
The path which a country/region takes towards the Emergence Phase will be idiosyncratic 
and contingent on the country/region’s specific historical development. For example, 
illustrated in the above diagram, a country which begins the TARGET approach in the 
Background Phase (Country A) will advance differently than a country which begins in the 
Pre-Emergence Phase (Country B). 
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Brief Examples of the Co-evolution of the Sector Drivers  
In the Israeli case, co-evolution is most clearly seen in the development of venture capital (VC) 
alongside the information technology sector and their later implications for the biotechnology 
sector. Venture capital promotion was instituted twice, with the first program (Inbal) failing in the 
sense that its value generated remained low. Additionally, it suffered from bureaucratic 
problems. The program did, however, stimulate learning in the private sector and the public 
sector which led to a more successful VC program under Yozma. The evolution of policy 
knowledge, along with the evolution of private sector experience in entrepreneurial activity, led 
to success the second time around. This success was also dependent on circumstances such as a 
high influx of skilled immigrants, and a military R&D background which provided technology to 
be exploited. A venture capital  industry then helped to facilitate early development of the 
biotechnology sector, demonstrating a further link between system components.  
A second clear example of co-evolution is presented in the case of Scotland and the generation of 
new firms in biotechnology. Academic excellence provided the source for new firm development 
in Scotland which continued to develop with the recognition of star scientists in the Scottish R&D 
system. Firms were created out of this mostly using public venture and angel money, as well as 
other public supports for creating new firms. Eventually, a set of Scottish companies were able to 
attract funding from outside of Scotland for large valuations not possible with local investors. The 
success of these firms, and the creation of other life science based firms in Scotland, meant that 
policy efforts turned away from firm creation and began focusing on firm growth. Unfortunately, 
a number of Scottish firms failed. With fewer firms being created, investors from abroad had no 
reason to stay in Scotland. In this sense, academic, financial, and policy drivers were evolving 
simultaneously and impacting one another. Moreover, Scotland’s sector evolution was impacted 
by the continuing development of the Cambridge and South East England biotechnology sectors. 
With these sectors continuing to grow and produce new firms, a slow downturn in Scotland 
provided little incentive for investors from London to look for Scottish opportunities despite past 
promise. This experience has also meant that entrepreneurial activity in Scotland has shifted away 
from drug discover to lower risk endeavors. 
 
Previous interventions in the innovation system have created various path dependencies 
and trajectories that will influence both future policy as well as the development of the 
sector. This also shows the significance of proper assessment as to the position of the 
country/region. Different policy schemes will be needed for different starting points, and 
policymakers should be careful when comparing local progress to that made in other places, 
as the idiosyncratic nature of the Life Cycle means that there is no one development path to 
expect and imitate. 
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4. The Sector Drivers 
The Industrial Life Cycle Approach combined with the sector drivers provides a holistic perspective 
of the biotechnology sector, which assists in understanding how each of the drivers are tied together 
and co-evolve over time.  
The Sector Drivers are the ‘engines’ which move the sector from one phase of the Life-Cycle to the 
next one. The drivers presented in this Toolkit are those which have been determined as important 
throughout the different phases of the life cycle:  Science, Training, Commercial, Financial, Human 
Resources and Other Institutions. The drivers are described at each evolutionary phase to help 
policymakers evaluate what phase each of their own country/region’s Sector Drivers is located. 
Mapping each of the Sector Drivers and realizing its position on the Life-Cycle is essential for the 
policy program to address the real needs of the country/region.  
Sector Drivers at the Background Phase 
Science A strong basic R&D system either public or private exists, though in most cases this will 
be in public institutions such as universities. This need not be in specific biotechnology areas at this 
stage. A scientific research base is necessary to create both absorptive capacity in R&D structures and 
the necessary science which would lead down a path of specialization in biotechnology or other 
techno-innovation paths which may appear. A funding base for R&D should also be present, 
preferably organized around competition to ensure that the best projects and scientists are supported 
and retained in the system. 
 
Training A system of training producing skilled personnel in the sciences exists in order for the 
local system to maintain its R&D capacities or for utilizing science produced in the system further 
down the value chain. 
 
Commercial Experience of public and private sector use of science produced by the 
abovementioned R&D system is a necessary background condition, demonstrating a local path for 
technological uptake by consumers. 
Additionally, industrial capacity in 
manufacturing, and preferably in higher 
value-added activities, such as product 
development or quality control is a good 
background condition as it shows experience 
in quality manufacturing, the presence of a 
skilled workforce and management and the 
An interesting example is Ireland, which has 
been attempting to build its life sciences 
industry based on its quality manufacturing 
experience and facilities, with science and 
training catching up to these features.  
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existence of firms which would act as either the developers of new technologies or partners/suppliers 
for new ventures. The Commercial driver should also include experience in transnational economic 
relations and collaborations, particularly as industries such as biotechnology will not be contained in 
one economy in the sense of knowledge creation, investment, and sales. 
 
Financial Financial structures should be present for the transfer of capital towards new ventures 
or established ventures looking to take on new risk, and for investors to realize returns. This does not 
need to include a fully functioning venture capital market at this stage; however, the institutional 
structures, laws and regulations should be present to facilitate the creation of such a market if 
necessary.  
 
Human Resources A labour market should be present which allows for the movement of 
skilled personnel, their attraction and retention. 
 
Other Institutions Clarity in regulatory systems such as Intellectual Property regulations, or 
regulations which may impact health products should be present. Lack of clarity in these areas 
creates disincentives for potential investors and potential entrepreneurs, particularly in high risk 
sectors. Related to the abovementioned public and private use of science, a working system of health 
care (public or private) should be a basic background condition as it provides a system of hospitals 
that offer a domestic market, and potentially further R&D capacity including clinical trials. Finally, a 
political system with a history of cooperation is useful as this will lower the risk of erratic policy 
changes which affects the economic arena in which entrepreneurs and investors find themselves in. 
 
Excellent science in conjunction with financial support for R&D and the availability of VC 
funds are the basic elements in the development of a biotech sector. 
When excellent science is not well established and there is no biotech industry in place at early 
stages of a biotechnology sector’s development, policies targeting finance and the 
establishment of start-ups as an entry-point, are questionable. 
 
For example, Scotland’s start-up finance was mostly centred on angel investors and public 
sources of support, later attracting venture capital. Sweden, on the other hand, moved 
forward with established public investors such as Industrifonden, direct and indirect 
support from established parent firms, as well as the publicly funded creation of a local VC 
market. 
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Sector Drivers at the Pre-Emergence Phase 
Science Public and private R&D sources at this stage begin specializing in biotechnology, with 
both basic and applied science being produced by the R&D system, particularly with an eye towards 
eventual commercial use. A pool of scientists in the different disciplines which make up 
biotechnology are present in the economy and star scientists are being recognized both locally and 
abroad for the work they do in the sector.  
 
Training Graduates and new researchers in the biotechnology sector are increasing, supplying 
the scientific, technical and support skills necessary for both research and industry. 
 
Commercial Closely tied to the scientific system, methods of technology transfer are generally 
developed more fully during this phase, facilitating the use of new knowledge by industry. 
Entrepreneurial activity has begun in earnest during this phase, either through the development of 
start-ups or spin-offs, directly from academia or from already existing firms and industry. 
Furthermore, key individuals with experience in the sector or who have been successful and can 
‚reinvest‛ their knowledge in the sector, should become visible during this period; from these 
individuals the first set of serial entrepreneurs may emerge to further the sector’s commercial 
development. Large pharmaceutical firms or other large firms in the biotechnology sector should also 
begin to settle in the local economy at this stage, recognizing the value of local inputs and adding a 
further source of attraction to other potential investors.  Finally, related service and support 
providers should begin to appear at this stage alongside the increasing number of biotechnology 
firms. 
 
Financial Finance for start-ups should not only have begun to appear by this phase but have 
begun to be institutionalized in some form; examples can be the formation of public venture capital 
schemes, more organized angel activity, or increasing private venture capital investment. 
 
Human Resources The provision of skilled workers continues, with an increase in those 
with business skills, in addition to maintaining the system's R&D skills. 
 
Other Institutions Trial infrastructure for new health related products will likely begin to 
appear at this stage. Also, while key individuals will have begun to appear in the commercial world, 
key individuals or champions may also appear in other areas such as the policy realm; policy support 
(direct or indirect) and recognition of the sector should be well-established by this phase. 
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Sector Drivers at the Emergence Phase 
Science The science driver at the Emergence Phase is an extension of the previous phase’s 
conditions. R&D work expands, and star scientists continue to garner recognition. Furthermore, more 
top quality researchers are attracted to the locality to participate in research. 
 
Training Extension of the Pre-Emergence phase: A system of training producing skilled 
personnel in the science exists in order for the local system to maintain its R&D capacities or for 
utilizing the science produced in the system further down the value chain. 
 
Commercial A pipeline of products is apparent and moving through the research and, more 
importantly, the development processes are on their way to market. Dependence on one or two 
products is lessened, and more companies are becoming multi-product/service providers. The 
emerging market for biotechnology products is gaining some stability and will not collapse with the 
failure of some of the companies involved, or some of the products failing to pass through different 
development hurdles. Manufacturing in the biotechnology sector is expanded and may involve a 
separation from commercial R&D entities. Links between firms at this stage become more stabilized 
in the sense of collaboration as well as supply relationships, and there is a growing recognition of the 
Background Pre-Emergence Emergence 
The Industry over Time 
Path of Country A 
The Industry Life-Cycle and the Sector Drivers 
Path of industry development from the moment TARGET approach begins  
Science 
Training 
Commercial 
Financial 
Human Resources 
Other Institutions 
Position of the Sector Drivers in regards to the Industry Life-Cycle 
 The Drivers change with the industry from Phase to Phase. As 
the drivers evolve to a certain point, the industry will 
transition to the next phase. Chapter 5 describes the Policy 
Dimensions that details how to approach the Drivers. 
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local sector as a ‚unit‛ to which actors belong.  Start-ups and spin-offs will continue to be created, 
and serial entrepreneurs should have appeared by this stage. 
 
Financial The locality’s attraction to investors becomes more established, no longer based on 
one-off opportunities or pleasant surprises. Start-ups and spin-offs continue to receive funding, and 
growth capital becomes available as well. 
Human Resources There should be a higher amount of employment ‚churn‛, with skilled 
labour moving between companies, coming into the local economy as well as moving to other 
established biotechnology sectors abroad – tacit knowledge exchange and experience will increase in 
the system in this manner. 
 
Other Institutions Some elements of public support may begin to be phased out, however 
new policies or concerns may emerge such as how to retain local ventures, and how to increase access 
to foreign markets. 
 
The existence of top quality scientific research is a key precondition for the development of 
the biotechnology sector. However, there have been relatively successful biotechnology firms 
based on less-than-revolutionary science, which highlight the importance of industry 
applicable science.  
Simply building up the science base for the sake of having the best science may not lead to 
biotechnology success – the science must be applicable to industry and commercializable.  
 
TARGETED R&D POLICY 
www.targetproject.net 
 
 
 
 Background Phase Pre-Emergence Phase Emergence Phase 
 
Science 
 
A strong basic R&D system 
(mostly in academia), not 
specifically in biotechnology. 
 
   
Public and private R&D sources begin 
specializing in biotechnology, with 
both basic and applied science being 
produced by the R&D system, 
particularly with an eye towards 
eventual commercial use. 
R&D work expands and star scientists 
continue to garner recognition. 
Top quality researchers are attracted to 
the locality to participate in research. 
Training 
A system of training skilled 
scientific personnel is present.   
Graduates and new researchers in the 
biotechnology sector are increasing. 
Extension of the Pre-Emergence phase. 
 
Commercial 
Experience of public and 
private sector use of science 
produced by the R&D system. 
Industrial capacity in 
manufacturing, and preferably 
in higher value-added activities.  
Experience in transnational 
economic relations and 
collaborations. 
Entrepreneurial activity. 
Key individuals with experience in the 
sector or who have been successful 
and can ‚reinvest‛ their knowledge in 
the sector become visible.  
Large pharmaceutical firms or other 
large firms in the biotechnology sector 
begin to settle in the local economy. 
Related service and support providers 
begin to appear. 
A pipeline of products is apparent and 
the development processes are on their 
way to market.  
More companies are becoming multi-
product/service providers.  
Links between firms become more 
stabilized.  
Start-ups and spin-offs will continue to 
be created, and serial entrepreneurs are 
appearing at this stage. 
Sector Drivers in each Phase of the Industry Life-Cycle; Part 1 
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 Background Phase Pre-Emergence Phase Emergence Phase 
Financial 
 
No fully functioning venture 
capital market.  
Financial structures are present 
for the transfer of capital.  
Institutional structures, laws 
and regulations existing.  
A Finance for start-ups is 
institutionalized in some form: the 
formation of public venture capital 
schemes or increasing private venture 
capital investment 
 
The locality’s attraction to investors 
becomes more established 
Start-ups and spin-offs continue to 
receive funding and growth capital 
becomes available.  
Human 
Resources 
A labour market which allows 
for the movement of skilled 
personnel, their attraction and 
retention. 
 
 
The provision of skilled workers 
continues, with an increase in those 
with business skills 
 
Higher amount of employment 
‚churn". 
Skilled labour moving between 
companies.  
Tacit knowledge exchange and 
experience.  
Other 
Institutions Clarity in regulatory systems. 
A working system of health 
care.  
A political system with a 
history of cooperation. 
Trial infrastructure for new health 
related.  
Key individuals or champions 
appearing in the political or policy 
realm.  
Policy support and recognition of the 
sector.  
Some elements of public support may 
begin to be phased out. 
New policies emerge such as how to 
retain local ventures. 
Sector Drivers in each Phase of the Industry Life-Cycle; Part 2 
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5. The Policy Dimensions 
With a basic understanding of the Industry Life-Cycle and the Sector Drivers which move the 
biotechnology sector from one phase to the next, policymakers are subsequently provided with a 
description of eight policy dimensions. These policy dimensions are seen as key decisions points for 
policymakers and can be divided into strategic and tactical decisions. 
The first four dimensions are strategic because they establish the call to pursue a biotechnology sector 
actively and the broad vision that efforts will work towards achieving. Once these high level 
decisions are made, the specific steps needed to fulfil them will have to be carried out,  i.e. the tactical 
decisions and steps. The strategic level aspects may be determined by politicians, ministers, leaders of 
industry, or high ranking and influential civil servants who can influence government beyond 
specific policies. The tactical decisions discussed will likely be carried out by policymakers ‚on the 
ground,‛ trying to match their actions to the vision they have been charged with working towards.  
The following Diagram illustrates the policy process in terms of the different Policy Dimensions. As 
seen, the Strategic decisions are taken at the very beginning of policy implementation and shape the 
Policy Dimensions 
Strategic Decisions 
High level Decisions present through 
the policy process. 
Tactical Decisions 
Measures taken ‚on the ground‛ to match 
actions to vision. 
Assessment 
Stakeholders 
Vision Leadership 
Entry Points 
Measures Evaluation 
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path of advancement towards the policy goal. There are different possible goals for a biotechnology 
sector and the Strategic decisions will determine which goal is being targeted. Once the Strategic 
decisions have been made, implementation begins and tactical decisions are taken. New tactical 
decisions are taken for each policy program. As time progresses the sector itself changes and the 
tactical decisions must be changed appropriately. For instance, if the country/region works under a 5-
year policy program, when the first ends and a new one begins – there will be a need to revise the 
previous tactical decisions according to the new situation (a mechanism of on-going assessment 
during this period of time, not just at the end, would also be recommended). It is important to note 
that Strategic decisions might also need revision, especially if assessment suggests that the targeted 
goal might not be feasible at the moment. This will be clarified below.  
 
Strategic Policy Dimensions 
1. Realistic Sector Assessment  
 
- A review process: Before deciding to carry out policy intervention with a functioning 
biotechnology sector as its goal, it is crucial that an objective assessment be carried out to 
establish at what phase the sector and national/regional economy is in. Using the Industry 
Life-cycle approach, part of the Realistic Sector Assessment must be an analysis of the Sector 
Drivers already existing in the economy and which could play a role in the emergence of the 
sector. The assessment process is given primary importance here in that it sets the targeting 
process on the right track. The assessment is a comprehensive review process which concerns 
any possible component of the sectoral system of innovation.  
 
Taking 
Strategic 
Decisions 
Taking 
Tactical 
Decisions 
Taking New 
Tactical 
Decisions Goal A 
Goal B 
First Policy Program Begins First Program Ends; Second Begins 
The Policy Process 
Taking 
Strategic 
Decisions 
Time 
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- Sector Drivers: The assessment should consider the Sector Drivers detailed in chapter 4: the 
science base (bio and medical), institutional and political framework already existing (e.g. 
support for targeting, tech transfer capacity), innovation policy budget, entrepreneurial 
capacity, industrial and public health infrastructure, small business finance, and regulation 
(i.e. IP, ethical approach to things like stem cells and risk-related factors especially in relation 
to clinical trials). The assessment process should include an assessment of global trends and 
competition in order to identify opportunities and competitors.  
 
- The Capability to secure a long-term commitment: When going through the assessment, one 
political issue which must be determined concerns the capability to secure a long-term 
commitment; this is vital in the biotechnology sector, where knowledge translation and 
product/service development takes 10-20 years, requires major capital investments (often 
beyond the capacity of many countries/regions) and involves very high rate of failure. Also, 
concerning the science base assessment – a variety of different measures can be used, such as 
publications, citations, movement of skilled people, etc.; but it is not only quantitative 
measures which are important, but also qualitative dimensions such as the divisions 
between public and private science, the presence of networks and communication between 
them and the structure of the public science base. Furthermore, the assessment should 
consider both absolute and relative measures. 
- The assessment's outcome: The outcome of this process should lead the country/region to 
decide: 
  
 Do we want to consider targeting biotechnology? 
Policymakers must take into consideration that the assessment may result in the 
conclusion that acting on developing a biotechnology sector may not be the best route 
for their particular country/region. However, if the decision is made that intervention 
should be pursued regardless, actors must seek to first establish pre-conditions, namely 
to create the missing Sector Drivers. As a result, the process will be longer and, while it 
may not require more buy-in from different stakeholders, will require more patience 
and a longer-term view by those actors pursuing the strategy.  
 What should the exact goal be? (see next point)  
 
 
 
  
  
           See the list of questions which policymakers can use as a guide to their initial 
assessment at annex 1. 
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2. VISION  
-Definition and profile: A decision to target a particular sector or industry requires a definition of 
that sector and some profile of how the sector will look after the policy is implemented.  
-Conceptualization of the policy process: Furthermore, the conceptualization of a policy program 
must be multidimensional and systemic in terms of how different components in the economy 
influence the targeted sector, stakeholder incentives, and the potential systemic changes or 
adjustments needed. This conceptualization is necessary regardless of the type of interventions 
that may or may not take place, as it provides a long-term vision that allows for flexibility; it 
would allow for later interventions to be designed as necessary in a way that would not block or 
misalign earlier stage interventions.  
-Alternative goals: The vision must 
address the different possibilities and 
capabilities of the country/region and 
to designate a Goal for the process. 
There are various forms a 
Biotechnology sector might take and 
policymakers need to take into 
consideration different possible goals. 
Alternate goals should be considered 
if system assessments indicate 
extreme difficulty in achieving a fully 
functioning sector, or if unintended 
developments arise in the life cycle 
requiring a change in vision.  
 Full Bio cluster  
 Niche Bio Cluster  
 SME Generator  
 Bio Supply or Service (participation in single part of value chain)  
 Partner Technology (not bio, focus on a different but potentially collaborative technology)  
-Broader Objectives: Just as important is the need to understand how targeting a sector forms part of 
broader objectives for the national or regional economy. Without this vision of its part in the broader 
economy, such a policy process runs the risk of being seen as a short-term fad or policy whim and 
would not be given the long-term resources required. Too often, high level policymakers decide to 
The vision should reflect not only decision-
makers’ ‚ambition to bio‛ but also the reality of 
cases assessment which delineate key capabilities 
of the country or region.  
One of the key lessons derived from our case 
studies is that achieving a functioning life 
science cluster with any degree of critical mass 
will require a minimum of 20 years investment 
and reinvestment. It may therefore be necessary 
to aim for more modest goals. Such endpoints are 
not less valuable in that they may provide a more 
realistic option for return on investment, and may 
also lead to new potential pathways in the future. 
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pursue their ‚ambition to bio,‛ aiming for a world class, competitive, fully innovation cluster without 
properly understanding the timelines and resources needed. 
-Regular system re-assessments: This is where frequent assessments become vital. In order to realize 
if a Goal is feasible, policymakers need to assess their progress on an on-going basis, especially when 
switching between policy programs. Thus, regular system re-assessments (along with policy 
evolution) are important features of the Target process, along with subsequent opportunities to adjust 
the Goals. 
3. Leadership  
-Kicking-off the Target effort: To begin the process, entrepreneurial actors are needed to kick-off the 
Targeted effort, regardless of whether they are involved in the management of the subsequent 
process. Such a decision could be taken by any entity or body that has official recognition such as a 
ministry, committee or even a private body that represents the field.  
-Strong Unity: What is important, and creates a major challenge in achieving a coherent targeted 
strategy and establishing a roadmap, is the acceptance of a common mission or overarching goals by 
a multitude of parties. On the government/political side this means acceptance from multiple political 
parties, as well as other influential ministries and agencies active in the economy, but it should also 
include acceptance from private and third column stakeholders (e.g. universities and research 
institutes) in order to better facilitate coordination and less interference during the operation of the 
strategy itself. A minimal condition should be strong unity in either the public or private sector in 
this regard if not both. The condition of unity in one or both of the public and private sector should 
be an early part, if not precede, the early pre-implementation analysis described above.  
 
Taking 
Strategic 
Decisions 
Taking 
Tactical 
Decisions 
Taking New 
Tactical 
Decisions Goal A 
Goal B 
First Policy Program Begins First Program Ends; Second Begins 
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The Policy Process: Vision Revised 
Taking 
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4. A Coordinating Body  
A Coordinating Body is here described as an organization (or consortium) charged with carrying out 
the Target strategy and delivering or advising on different policy measures necessary to achieve the 
Goals. As such, it involves decisions at the strategic and tactical level in terms of how to construct the 
Coordinating Body in terms of its institutional structure, but also in terms of how the knowledge 
creation, experience and data it gathers feeds back into strategic outlook and tactical policy 
construction. The Coordinating Body should be able to translate this information into a roadmap and 
to create the drive for such a roadmap to be implemented. Additionally, the Coordinating Body 
should be responsible for monitoring progress, ensuring on-going learning, enabling feedback from 
different stakeholders and constructing policy that will deal with any blank spots in the roadmap as 
information becomes available. Because of the undefined nature of some of the new technology 
markets and business plans, ideally a Coordinating Body could engage in a conscious consideration 
of sector context, strength and a 
creative process of projecting possible 
paths that are realistically obtainable 
in the economy. From that analysis, 
the Coordinating Body can then help 
to guide the next step of strategy.   
 
The TARGET approach can be understood as having two chief characteristics. Recognizing that the 
Innovation System is non-static and develops in a non-linear way is the first and basic one. The 
Extended Life Cycle model described in Chapter 2 of the Toolkit captures this well. The second 
characteristic, which follows from the first, has to do with the way policymakers should understand 
their engagement with the Innovation System. Instead of envisioning the act of intervention as one 
which takes place during a single moment in time, policymakers should understand their 
involvement as an ongoing process of mutual change. This involvement is captured by the different 
decision points or Policy Dimensions described in Chapter 3 of the Toolkit. All policy dimensions 
refer to decisions that policymakers will have to address repeatedly as the industry develops and 
policy schemes change and adopt.  
The different policy dimensions, such as Identification of Stakeholders or Selection of Entry Points, 
point to the multilayered effort which Targeting involves. In order for a biotechnology sector to 
develop, there are different Sector Drivers which must be addressed. These fall under the 
responsibility and influence of various ministries, government agencies and private entities making 
the process of targeting a multi-agent one. Thus, the non-static nature of the system together with the 
repetitive intervention process makes it clear that coordination is highly important. However, for 
coordination to be successful there is need for both a flow of information and the accumulation of 
knowledge.  
The Coordinating Body has to be able to ask the 
hard questions and make the difficult decisions 
which may not necessarily appeal to short term 
political interests. Without this ability, the 
difficulty of actively pursuing a biotechnology 
sector is increased.  
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The effectiveness of a designated Coordinating Body was clearly recognized in the case of Singapore. 
At the beginning of 2000, there was no Strategic-Level of policymaking for R&D in the country. 
However, headed by a prominent political figure the Economic Development Board (EDB) managed 
to act as a de facto Coordinating Body for targeting biotechnology. The EDB is a government agency 
working under the Ministry of Trade & Industry responsible for the support of business, industry 
and global trade. Its declared mission is to establish Singapore as a business hub of the region. 
Following his vision of creating a biotechnology sector, the head of the EDB at the time, Philip Yeo, 
acted as a ‘policy champion’ and negotiated a 5-year working plan for the establishment of 
biotechnology capabilities with different policy functions within the system.  
In a sense, the EDB acted as Singapore’s Coordinating Body – gathering information from different 
ministries, accumulating knowledge about the biotechnology sector and coordinating between 
elements of the innovation system to create a holistic policy program. The first phase of Singapore’s 
BioMedical Initiative (BMI) was considered a success from a policy perspective after which the 
Ministerial Committee was established in 2006 to decide on the next phase. The Committee 
recognized the effectiveness of having a coordinating body within the innovation system and created 
the National Research Foundation (NRF), which acts as Singapore’s Coordinating Body for the entire 
R&D system overseeing the progress of policy programs, deciding on new ones, collecting 
information and accumulating knowledge on these processes.  
Although Singapore’s case is unique, instances of the functioning of various sorts of coordinating 
bodies were recognized in other case studies. While the specific structure of the coordinating body or 
its institutional position within the innovation system may take different forms, there are features 
which such a body should be able to perform: 
FEATURE 1: The Gathering of Information and Accumulation of Knowledge 
Without a clear picture of ‘things on the ground’ it will be very difficult to realize what the proper 
alignment of the different stakeholders is. Without learning from past experiences, both locally and 
globally, it will also prove difficult to devise way of acting. Thus, as mentioned above, for 
coordination to take place information must be gathered and knowledge accumulated.  
A. The Coordinating Body needs to be positioned within the innovation system so it can tap 
into the flow of information. This can take many shapes. Currently in Singapore the NRF is 
positioned at the top of the policy structure, ensuring that all information flows upwards and 
centers at the top. However, this does not have to be the case. Again, in 2000 the NRF did not 
exist and the EDB, which is positioned at the bottom of the policy structure (a government 
agency under a ministry), managed to tap into the flows of information nonetheless. This 
happened due to Phillip Yeo’s personal connections. He was able to establish channels of 
communication with heads of other agencies and ministries above him.  
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Thus, while positioning the Coordinating Body at a strategic level of policy making, such as 
the Prime Minister’s Office, there are also other alternatives. The exact position of the 
coordinating body will be conditioned on historical developments and contingencies which 
are idiosyncratic to each country and region. However, policymakers aiming for an effective 
body will have to ensure that it can gain access to information. Be it due to institutional power 
and authority, personal connections of prominent figures within the body, or other 
arrangements- this must be taken under consideration. 
 
Gaining access to the flows of information will enable the Coordinating Body to perform a 
Realistic Sector Assessment, which is one of the most crucial policy dimensions. Having the 
ability to observe and follow the progress of different ministries, commercial enterprises, 
infrastructure, etc. will ensure that the Coordinating body can form a sound picture regarding 
the biotechnology cluster in the country/region in terms of its position on the Life Cycle. 
Ideally, dedicated personnel will be devoted to these ongoing tasks of keeping a real-time 
picture of progress available. This will both support assessments as well as the design of future 
policy programs. 
 
B. The Coordinating Body needs to accumulate a Body of Knowledge on the process of 
Targeting. 
Tapping into the flows on information within the innovation system is crucial, yet not enough. 
In order for the Coordinating Body to be able to assess incoming information it must create a 
body of knowledge for reference. This includes keeping record of past experimentation and 
policy schemes within the country and abroad, but it also includes actively researching the 
field being targeted.  
 
Biotechnology is evolving all around the world and there is yet to emerge one dominant policy 
design, thus policymakers within the Coordinating Body need to evaluate and record progress 
that is being made in leading biotechnology clusters globally. This can be established in many 
ways. In Singapore, for instance, the EDB actively invested in foreign biotechnology 
companies to gain insight knowledge. This could also be performed by an outsourced 
committee of experts that include prominent people from different countries. Such advisory 
committee can exert its judgment on the information that flows inwards and provide the 
knowledge needed for amendments and future interventions. As with other functions, the 
specific institutional arrangement that materializes is less important. The issue is recognizing 
the need for such a function within the Coordinating Body.  
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FEATURE 2: Political Independence and Long-Term Commitment 
The process of targeting the emergence of a sector, especially a biotechnology one, is long and 
challenging. In Singapore, for instance, the country has been actively investing in the emergence of 
the sector for more than 10 years and, arguably, it has still to reach the level of Emergence. Similarly, 
in Israel, the sector has been growing since the 1980s and is, arguably, on the verge of emergence. 
Thus, the decision to target must be understood as one for the long-term. The Coordinating Body 
should be the institutional framework that provides such long-term commitment. This can take 
different forms, but this is a key capability that must be worked out when the Coordinating Body is 
established.  
 
Ideally, the body responsible for the development of the innovation system should enjoy similar 
political autonomy as central banks do in many countries. While this is understandably difficult to 
negotiated, the separation of strategic decision from short-term partisan politics should be attempted. 
An important point raised by many seasoned policy experts in the Life Sciences was that the 
Coordinating Body had to be able to ask the hard questions and make the difficult decisions which 
may not necessarily appeal to short term political interests. Without this ability, the difficulty of 
actively pursuing a biotechnology sector decreases. 
 
FEATURE 3: Operational Role and Flexible Intervention 
Ideally,  the  Coordinating Body should  benefit  from  having  the  necessary  political  will  (and  
financial support, which we will mention below) to operationalize the strategy. Furthermore, the 
Coordinating Body should be divided strategically and operationally, with one body or division 
working to determine strategic level directions and another to operationalize and deliver programs. 
This separation can be done by either having an umbrella organization operating alongside other 
organizations (as is the case in Ireland) or one organization which is internally divided (for e.g. 
Scottish Enterprise).  
 
The separation of these functions requires a crucial linking mechanism in order to keep a very 
effective feedback and evaluative loop. The benefit of separating the functions allows for the strategic 
level body to maintain the strategic objectives while absorbing environmental changes and new 
information. This enables the Coordinating Body to adjust the details of the policy roadmap to better 
reach the end vision or result. Because of the undefined nature of some of the new technology 
markets and business plans, ideally a Coordinating Body could engage in a conscious consideration 
of sector context, strength and a creative process of projecting possible paths that are realistically 
obtainable in the economy. From that analysis, the Body can then help to guide the next step of 
strategy. The role of the operational side of the Coordinating Body will depend on the pre-conditions 
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already present in the regional innovation system and whether or not market failures will be 
additional to structural corrections that must be addressed. An important role is that despite the 
business/academic/research culture in the location, the Coordinating Body must seek to build and 
strengthen networks between stakeholders as part of its program executions, not simply provide 
funding or incubation services, or other direct activities. Including network building activity would 
help to create opportunities for private actors to take on more responsibility or, at the very least, 
allow for Coordinating Body programs to have more deliverable impact through indirect spillovers. 
 
In order for the operational side of the Coordinating Body to have positive impact in real time, it is 
recommended that it will be able to spend funds in a flexible way. This means that unmarked 
allocation of funds is necessary. While this brings difficulties from a political perspective, if Feature 2 
has been established it could become easier to maintain. For instance, in Singapore, the strategic body 
was able to spend an agreed-upon sum of resources on ‘filling gaps’. It is not possible to address all 
future challenges within a pre-devised policy roadmap and different problems within the innovation 
system are likely to manifest. Without this flexibility in the allocation of funds, these problems will 
only be addressed in the next funding-cycle which is locally idiosyncratic and depends on the overall 
budgeting cycle. A Coordinating Body that can spend resources willingly to establish new support 
schemes can provide better assistance to the different players and ensure that the overall strategy is 
being addressed. Acknowledging the dynamic nature of both the science involves as well as the 
development of knowledge-based sectors, flexible intervention is one of the Coordinating Body must 
important features.  
Tactical Policy Dimensions 
1. Identification of Stakeholders  
While discussed at a strategic level regarding consensus for the policy process, it is important to re-
state the need to identify as many stakeholders in academia, the public sector and private sector who 
currently, or might in the future, contribute to innovation in the sector selected, as well as any 
institutions which may have an indirect impact on the sector (e.g. groups which may influence ethical 
considerations in scientific development but are not involved in research or commercial 
development). This is particularly important as the most successful systems of innovation are those 
which demonstrate high levels of coordination between stakeholders, and take advantage of the 
systemic nature of innovation and technological development. This is important not only for strategy 
buy-in, but also to determine which policy measures should be aimed at, who they may impact, and 
how stakeholders may be added, disappear, or change over the course of the strategy. 
2. Identification of Entry-points  
Entry points for any policies or interventions in attempts to develop an industry must be defined, and 
there must be minimal conditions present for action at an entry-point to be effective. The entry-points  
TARGETED R&D POLICY 
www.targetproject.net 
 
 
 
45 
 
are the particular areas that policy will be implemented to enact direct change or amplification of 
activity. Realistic chances of influence must be assessed, both in the specific entry-point and the 
overall system – for example, it would be pointless to select venture capital creation as an entry point 
if there is no knowledge available from which to create start-ups.  
The decision of how to choose the particular entry-points must also consider whether the correct 
entry-points are those ‚low-hanging fruit‛, or those which may be more difficult but have a longer-
term positive influence on the innovation system. On the one hand, while a longer term vision is 
encouraged for a targeted approach, the long-term planning of resources and time commitment 
create challenges for policymakers. Short-term goals may be an easy success, but may not be best for 
the system. However, a different consideration may be that low-hanging fruit can create further buy-
in from stakeholders and therefore allow for more long-term commitment. Practical versus 
theoretical consideration must therefore be considered and policymakers should develop this 
awareness. 
 
3. Design and Execution of Measures  
The point above regarding effective policies at specific entry-points is important to the design of 
measures take to reach the selected goals. It is also important to keep in mind the stakeholders who 
may be involved both as providers and as ‘clients’ of the measures. It is recommendable to engage 
private sector stakeholders in the design and delivery of a measure, both because it enhances 
coordination and because it would help to create a realistic delivery time. For example, a measure 
designed to correct the funding gap for start-up firms would be hampered significantly if it was 
characterized by slow decision and delivery times; start-up firms would likely avoid such measures 
due to the resources required to fill out the necessary paper work, plus the prospect of missing 
market windows. On the other hand, radical systemic changes may require entrepreneurial solo 
action by public or private actors (e.g. an economic development agency, or a consortium of private 
sector actors) if potential partners are too risk-averse to cooperate. Regardless, to determine each 
possibility, stakeholder communication is necessary. 
Proper budgeting is also important to ensure effective implementation of a Target Strategy. The main 
concerns regarding budgeting are the difficulty to predict how much may be needed once a measure 
is launched, and whether or not the budget will be maintained in the long-term or potentially be cut.  
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In Lithuania, the Innovation Strategy stated that a full set of European Innovation Indicators 
that would be used to determine the strategy’s progress. While this may be useful, relying 
arbitrarily on this set of indicators would be problematic as the indicators were not selected 
based on their appropriateness for the Lithuanian setting, and therefore would not help to 
provide the specific feedback necessary for policymakers at the stage of development the 
economy is in. 
In Scotland, the evaluation mechanisms for innovation were altered from quantitative 
measures (of how many firms were created, money invested, etc.) to mechanisms which 
sought to determine how policies increase national gross added value. Changing evaluation 
mechanisms to judge the effectiveness of policies that were not planned with such 
mechanisms in mind meant that some policies may have been cancelled prematurely.  
  
4. Appropriate Evaluation 
An important but potentially overlooked part of a Target Strategy is the development of appropriate 
evaluation mechanisms. Evaluation is important because it allows for feedback to policymakers 
regarding policy effectiveness. More importantly, however, evaluation mechanisms should also 
provide feedback regarding the overall state of the industry as this would allow policymakers to 
maintain a systemic view of what is happening, and adjust the overall Target process rather than 
simply adjusting some specific policies. Therefore, what is necessary is a system of policy evaluation 
and system (re-)assessment while advanced evaluation mechanisms should be utilized, the 
evaluation of policies should rest both on indicators but also on a clear view of what the goal or 
intention the policy set rested on, whether the indicators appropriately capture that and whether 
these goals or intentions are still valid.  
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III. Benefits of the TARGET Approach  
Innovative activity will occur naturally to varying degrees in an economy. The degree of this activity 
will be directly influenced by the commercial capacity to exploit new knowledge; which in turn is 
affected by investments, commitments and knowledge made previously in the economy which may 
either fruitfully coincide with an emerging technology or conflict with it; and by external (global) 
market and non-market forces which affect the industry or sector. Moreover, because technologies 
like biotechnology encompass a fairly wide range of applications, the variety of the possible 
endpoints for the development of a biotechnology sector is equally wide. 
The variety of possibilities means that, while we can present different examples of cases which have 
pursued a biotechnology sector with some success, there is no one path to that success which can be 
determined from these cases. The TARGET approach will offer to the policy maker a way to work 
through this complexity.  
 
 The TARGET approach will help to understand how the different components of the system 
are linked and work together. 
 Understanding how components are linked will help to reduce the radical uncertainty of 
action, as well as present further opportunities for action which may move the 
biotechnological sector to a desired goal.  
 Understanding linkages in the context of the whole system means policymakers can try to fill 
in structural or institutional gaps, along with correcting market failures. 
 By understanding linkages between system components, and how actors work, supply and 
demand side policies can be applied. 
 The TARGET approach allows the policymaker to perceive how things evolve 
simultaneously. While a policymaker may be looking to cause a particular driver to evolve 
(e.g. science capacity), that driver will also be evolving because of the influence of other factors 
in the system which would have been acting upon it regardless of whether policy was directed 
towards it or not (e.g. past educational policy, presence of private sector R&D,  R&D policy) – 
the question is how much change will be produced by the different influences. 
 The policymaker will be able to predict how their interventions may impact on other areas of 
the system, besides their intended target. Because these drivers will evolve based on their 
context, an emphasis on regular and consistent system assessment will insure the necessary 
data flow for informed policy decision-making. Assessment will show how far the 
biotechnology sector has moved along its evolutionary path according to expectations derived 
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from other cases, and help policymakers understand the importance of timing regarding 
interventions; and identify unique characteristics which emerge in their own case.  
Policy challenges facing a Targeted approach in general 
Five general challenges to effective innovation policy encountered in the case studies conducted by 
the research team should be kept in mind: 
 
 Coordination – ensuring that stakeholders network and build on each others’ efforts to 
facilitate the functioning of the innovation system, filling any gaps and correcting any 
bottlenecks. 
 Flexibility and long-term commitment – sectors or industries that are targeted may be so 
new that the business plans and technology have not yet been completely determined. 
Therefore, flexibility in how these are addressed is essential. At the same time, many of the 
target interventions are systemic interventions, and institutional or system change requires 
a long-term view – so while flexibility is important, commitment to the overall strategy is 
also important. In other words, actors would ideally have the ability to change operational 
course if required, while maintaining long-term commitment to strategic goals. 
 Clarity, understanding and transparency – clarity in the objectives defined and set out by 
policymakers and stakeholders is essential. To achieve clarity, and to properly set out a 
roadmap, an understanding of the national and regional context as well as the 
requirements of the industries in question is essential. Transparency and communication of 
the objectives and path is important to help coordination, and to avoid conflict amongst 
stakeholders which may cause long-term commitment to be more difficult.  
 The ability to create an arm’s length lead organization(s) able to separate operational 
from strategic concerns, and able to maintain arm’s-length influence in a risk environment 
bound to produce a certain degree of failure. 
 Creating an environment accepting of risk and failure and allowing cycles of failure to be 
formed. 
Specific challenges in biotechnology 
Moving an industry or sector through phases of development and facilitating innovation require very 
specific attention to the needs of the individual sector, as mentioned above. While a general 
description of a TARGET approach is useful, the development of a biotechnology industry presents 
challenges which are unique to it, differing from sectors such as ICT. In fact, it would be inaccurate to 
refer to a single biotechnology sector, as the activities which are vying for commercial space range 
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from stem cell therapeutics to IT heavy medical devices to environmental and agricultural 
applications. However, because this group of activities depend on an interrelated body of scientific 
knowledge and skills, it is addressed by policymakers and private sector investors as a single 
category.  
As discussed above, a Targeted approach must be flexible, market focused, whilst still giving clear 
indications as to how policy and industrial coordination should proceed; due to the complexity of the 
industry, success and failure must be expected as specific policies or solutions which are attempted, 
and these may need to be readjusted. The main challenges encountered in the biotechnology sector 
are the following: 
 
 Regulatory system - The regulatory system of any potential markets will affect the risk 
structure and cost of developing and delivering innovation to markets, requiring any strategy 
to take this into consideration. Particularly for products that fall under therapeutic or drug 
discovery, however, the cost of pre-clinical and clinical trials drives up the cost of 
development and risk of failure. 
 Different risk profiles for different products - this creates a challenge since the incentive 
structure for different sectors within biotechnology will exhibit different risk profiles and 
therefore will affect how investors behave. Products such as medical devices or diagnostics 
generally exhibit a lower risk profile; however, they will also generally be low on the value-
added scale and long-term growth impacts. On the other hand, the risky profiles of 
therapeutics, and the extensive difficulty and cost of having potential products make it 
through all regulatory phases, means that products face a greater risk of failure during a 
longer period of time than other products, and investors, public and private, may simply wish 
to discard the risk. If particularly high risk sectors are to be pursued, then differences in 
incentive structures must be addressed.  
 Time-lines - Considering costs and the process of phased trials, the timelines for new 
biotechnology products, particularly in drug discovery in therapeutics are much longer than 
other technologies, and require constant commitment and monitoring. 
 A still developing business plan - Mentioned as one of the main challenges above for any 
knowledge based sector, this is perhaps one of the greater concerns in the biotechnology 
sectors. Much of the science is new and a large number of potential products must still pass 
through regulatory measures, therefore what is possible to deliver to market is constantly 
shifting. Furthermore, the value breakdown of projects, and the inputs and participants into 
the value chain are constantly being rearranged as a result of the growing complexity of 
science and increasing cost of research and development. The classic chemical-based large 
pharmaceutical firm approach can no longer be counted on as the best approach, and even the 
image of small firms acting as external laboratories for large pharma may need to be 
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reconsidered. This is the main reason that, while a targeted approach may define starting 
points and conditions, and subsequent actions, a degree of flexibility is needed for the end 
goal of the industry’s form. The societal goals, however, those which should be met by having 
a biotechnology sector, may still be defined. 
 A shifting landscape of firms - As implied above, the multinational pharmaceutical sectors, 
which may form part of or anchor a national biotechnology sector, has been undergoing 
extensive changes. Many firms have been acquired, moved or are changing their market focus 
in terms of the kinds of drugs they seek to produce and research they focus on. The R&D sites 
that have normally been associated with these firms are constantly pressured to remain 
attractive, and new potential sites are competing both for R&D and high value manufacturing. 
While the exact impact of this on other elements of the biotechnology sector is unclear, it 
creates a sense of instability that will undoubtedly impact investment decisions.  
 Public vs. private systems of health - The market dynamics for a set of products will be 
affected by whether there are multiple clients, a single client, competing clients or a single 
standard of care in a given market. Each of those has pros and cons that must be weighed, and 
will impact whether a product may even have a chance. For example, according to one 
comparison of the UK and US regenerative medicine markets, private healthcare systems may 
be a better environment for the development of new bio-based therapeutics because private 
hospitals and care providers are competing for patients and are more willing to use and 
advertise new technologies to attract patient/clients. In contrast, public health care is more 
reluctant to purchase new therapies if there is not an obvious and overwhelming difference 
with previous care. Another example compares the Canadian provinces of Ontario and 
Quebec and the public sector purchasing habits – Ontario’s system preference for generic 
drugs used in the local hospitals and clinics has meant that generic R&D and manufacturing 
industry arose in the province in contrast to Quebec which uses brand-name drugs and have 
managed to attract more brand-name pharmacy manufacturers. 
 Niche markets vs. Blockbusters - One of the main issues that therapeutics developers are 
wrestling with is whether to aim for a major blockbuster product that will be applicable to 
either a common disease or range of diseases and conditions, or whether they should focus on 
small niches in the health care system, or what may be considered orphan diseases. The risk 
and pay-off incentives of each differ, as well as the resources required for a company to carry 
something from research to the market. 
 Internal and external agglomerations of knowledge - For the biotechnology sector, many 
times agglomerations of knowledge, and knowledge exchange, will occur outside of a regional 
or national boundary. Researchers will many times exchange ideas with colleagues in other 
parts of the world where there is expertise, and the setting may not be enough to sustain the 
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knowledge requirements of an industry. As a result, scales of analysis and interaction are 
important to keep in mind when building and following a strategy for biotechnology. 
 Demand building - While many policies focus on supplying the necessary inputs for an 
industry, it should be considered whether there are any policies that can build demand and 
uptake for capital, skills or the final products that may create incentives for actors to become 
more involved. See above point regarding public versus private systems of health and policies 
that may have to work around institutional limitations. 
 Judging good science - Different cases claim to have ‚good science‛, but differ widely in 
comparison with each other in terms of scale and the available skills. What actually constitutes 
good science? And what is enough of a base for a strong biotechnology sector – whether in 
one niche or spanning several? This is stated in the assessment section above, but it is worth 
reiterating due to its importance. 
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IV. TARGET Case Studies 
The TARGET Toolkit is based on a number of successful case studies that were conducted during the 
first phase of the project. These case studies included the following regions/countries: North-Carolina 
(The triple helix), Singapore, Scotland, Israel and Sweden (Medicon Valley). Once the first version of 
the Toolkit was completed, four additional case studies were conducted in: Lithuania, Slovenia, 
Galicia and France.  
Following the completion of the first phase's case studies the research team entered a complex 
analytical process trying to find-out ‚general‛ elements for success. The variation of the cases and the 
fact that these cases represented different points on the biotechnology sector development path 
enabled the team to explore the importance of the Industry Life Cycle Phases (namely: the 
background, pre-emergence and emergence phases) as an approach for analysis. The cases of Israel, 
Scotland and Singapore, for example, demonstrated the great challenge of moving from the pre-
emergence phase to emergence. 
In almost all cases the development path exhibit various complexities that caused major shifts in the 
region/country’s innovation policies. In North Carolina, the policy goal has shifted from a full-
fledged cluster to a cluster that specializes in providing services to the biotechnology industry. In 
Israel, a shift was made from supporting the emergence of new biotech ventures to the support of 
public/private VC aimed at assisting companies to conduct phase III clinical trials. In Scotland 
failures to cross the advance phases of drug development resulted in retrenchment of local efforts 
towards less risky areas of the life sciences, such as medical devices and diagnostics. In Singapore, the 
difficulties in moving from the background phase to the pre-emergence phase and especially their 
failure in creating a vibrant environment of local bio-entrepreneurs, challenged policymakers and 
raised some important questions regarding the ability of policy, even in cases of almost unlimited 
financial resources, to lead the process of cultural change in the mid or even the long term. 
The analysis also revealed the importance of a crucial element within the innovation system, that of a 
Body of Knowledge, to the success of the cluster creation process. The demand for a body which 
is responsible for processing the knowledge which is gained during the implementation of a targeted 
initiative and for identifying and coordinating the relevant stakeholders is of specific importance in 
sectors that are characterized by an unknown development path. The lack of such a body may create 
sever delays in the cluster development process as was demonstrated in the Israeli case, where the 
time lag between the identification of the need to establish a public/private VC and launching an 
appropriate support scheme was more than 5 years. The Israeli case study revealed that this delay 
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was mainly due to lack of coordination between the relevant ministries and a missing function within 
the innovation system responsible for accumulating knowledge on the progress of the cluster creation 
efforts. On the contrary, the success of North Carolina to redirect its cluster creation efforts towards 
services was a result of an efficient body of knowledge that succeeded not only to analyze the 
required shift in the cluster orientation but also to reach consensus among the different stakeholders 
and to get their engagement to this direction. The creation of the North Carolina's Body of 
Knowledge resulted in an independent focal-point for strategic thinking, policy design, and 
implementation coordination. The structure of the Body of Knowledge enabled it to offer arm’s 
length and unbiased evaluation and policy design.  
Similarly, the success of Singapore to build the necessary drivers of the background phase could be 
attributed to its ability to set an effective body of knowledge which provided real time evaluation of 
the process, was able to direct the relevant players and in some cases to establish new agencies to 
bridge gaps when these were identified. 
Another identified factor for success was the ability of the policy system to take long term 
commitments. The case of Scotland clearly demonstrates the vulnerability of the targeted approach 
in cases where the ability of the policy system to take such long commitments is limited and is subject 
to political changes. On the other hand, the cases of Medicon Valley (started in 1995) and the case of 
North Carolina (started already in 1963) demonstrate the importance of the ability to ensure a 
coherent and continuous development process. This stability is of highly relevant for sectors whose 
development trajectories are relatively unknown, since in such cases the ability to measure success by 
pre-defined ‚success indicators‛ is much limited. Hence, politicians may easily define an initiative as 
a failure with the intention of shifting its funds to other purposes, while leaving limited space for its 
advocators. The Singaporean case demonstrated that the ability of the government to take long term 
commitments was an important factor in the decisions of foreign companies (mainly big pharms) to 
set up research centers in Singapore and for foreign individuals to relocate.  
The need for a strong science base is a key factor in the development of the cluster. This has been 
demonstrated in all cases. It was evident that the main bulk of the entrepreneurial activity, especially 
at the pre-emergence phase was a result of promising researchers coming out of the academic 
institutes. In some cases these entrepreneurs were incentivised to conduct translational research (e.g. 
Israel) while in other cases different actions aimed at maintaining the researcher’s ownership over 
intellectual properties developed by him were taken (e.g. Sweden). The importance of the science 
base became clear when analysing the Singaporean case (where policymakers had to recruit star 
scientists from abroad due to lack of local competence at the beginning of the process) and when 
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validating the Toolkit in, for example, Slovenia. In the Slovenian case the decision to target 
Biotechnology was in fact halted by this factor. 
Our case studies also demonstrated the need to define what is meant by ‚biotechnology‛. Many 
times the ‚ambition to bio‛ initially expressed by leaders may have been too ambitious for the 
country/region’s capacities or resources. This is why the importance of realistic system 
assessment becomes apparent. A successful targeted strategy does not have to be equivalent to the 
achievement of a full-fledged biotechnology cluster that covers a variety of products and services. A 
Target strategy may aim to achieve success in niche markets, creation of SMEs, or a more modest 
participation in the biotechnology value chain; the adequacy of the goals will correspond to what 
stage of development the region or country finds itself in terms of its scientific and commercial 
resources and experience. Indeed, the success of North Carolina has only appeared after its decision 
to focus on developing a service provider cluster. Similarly, the French case has linked the success of 
some of the French regions to their ability to focus on specific fields within the biotech-sector. On the 
contrary, part of the reason for Israel to be "stuck" at the pre-emergence phase with no real support 
system to take into the next phase has to do with a definition of biotechnology which was too broad 
and lacked clear focus.  
The links between Academia, Business and Government were found to be critical to the process of 
cluster creation. For example, in North Carolina as well as in Medicon Valley the process of targeting 
biotechnology benefited from a wide consensus among these three elements. Such a wide 
consensus resulted in high level of stability and an ability to effectively coordinate the process. The 
case of Lithuania as well as the case of Galicia has clearly demonstrated that failing to reach 
consensus among the stakeholders and coordinate their action may slow dramatically the 
development of the cluster and in some cases may even terminate the process. 
 
   
 
  
TARGETED R&D POLICY 
www.targetproject.net 
 
 
 
55 
V. General Lessons  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
The TARGET approach as an anchor for policy  
TARGET's evolutionary modeling of the biotechnology sector assists policymakers in 
conducting a realistic assessment of the sector. This includes an evaluation of the 
various drivers, the phase in which the sector is in and the measures required to lead 
the sector towards an emergence phase. TARGET Toolkit enables policymakers to 
comprehend the complexity of the innovation system, including the co-evolution of 
the different drivers, and therefore assist them in planning the appropriate policy 
measures and investments. The TARGET approach can also assist in developing 
shared modes of communication based on a common "evolutionary language", 
between the different agents and between policymakers around the globe. 
 
1 
A variety of possible goals  
A full-fledged biotechnology sector is not the sole goal for a targeted policy in the 
biotechnology sector. Other alternative goals could be niche bio cluster, SME 
generator, bio supply or service and partner technology. In some cases, more modest 
goals are better appropriate in regions or nations which are located at the background 
phase or are lacking some of the pre-conditions for establishing a full biotechnology 
sector. Therefore, the desired goal should be based upon realistic assessment both of 
the existing state of affairs and the capability to secure a long term commitment.  
 
2 
3 
A long time line for achieving a functional biotechnology sector 
One of the key lessons derived from our case studies is that achieving a functioning 
biotechnology sector with any degree of critical mass will require a minimum of 20 
years investment and reinvestment. It may therefore be necessary to aim for more 
modest goals. Such endpoints are not less valuable in that they may provide a more 
realistic option for return on investment, and may also lead to new potential pathways 
in the future. 
 
 
TARGETED R&D POLICY 
www.targetproject.net 
 
 
 
56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 Good science as a necessary but insufficient condition for a successful 
biotechnology sector  
The variety of case studies examined in TARGET project demonstrated the erroneous 
nature of the assumption that good science is the key-element for an emerged 
biotechnology sector. The role of the science driver is indeed crucial for a functioning 
innovation system, but it is far from being a sufficient one, since translating science 
into business models requires additional necessary components, such as strong and 
stable financial schemes and IP regime supporting new inventions. The ability to take 
advantage of existing assets and establish connections between the relevant 
stakeholders such as scientists, entrepreneurial, VCs and industrials cannot be based 
on extraordinary scientific developments alone.  Strong Infrastructure, qualified 
human resources and well-established financial schemes are required in order to 
attract investors and foreign companies 
5 The prominent role of public institutions and public financing  
Public institutions and public financing have a leading and evident role in establishing 
and promoting a biotechnology sector. The case studies have shown that the role of 
public finance is a crucial element for boosting the innovation system and is an 
inherent part of the economic development of the biotechnology sector. 
6 Investments are changing 
There is a clear shift in investment trends away from high risk projects which involve 
regenerative medicine, biotechnology based therapeutics and drug development, 
towards less risky products such as diagnostics, or device-based products. 
7 Global links as a crucial element for success 
Global links are necessary for to touching base with cutting-edge technologies, accessing 
global markets, achieving economies of scale, etc. MNEs can play an important role in 
establishing these global links. 
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8 The importance of a coordinating body 
A coordinating body responsible for filling the knowledge gaps, conducting on-going 
assessments and coordinating between the strategic level and the tactical levels is 
necessary for an effective targeted policy for the biotechnology sector. 
 
Consideration of both Supply and Demand side policies 
An effective policy requires that both demand and supply side policies will be taken 
into account.  TARGET project mainly approached supply side policy measures, due 
to its limited scope. However, demand side instruments, such as public procurement 
mechanisms, are an important component of policy for the purpose of creating and 
ensuring the existence of a market for the relevant technologies.   
 
9 
10 A variety of sub-sectors  
While there are specific challenges to the biotechnology sector (listed in chapter III), 
there are also specific challenges for sub-sectors within the biotechnology sector. The 
lessons of TARGET project are specific lessons for the biotechnology sector as a whole. 
It is important to keep in mind that implementing policy measures requires 
supplementary efforts that take into account the variety of "sub-sectors" that might 
need different treatment. 
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Annex 1: Guiding Questions for Realist 
Sector Assessment 
While these questions are posed as Yes/No questions, their answers are based on a thorough 
investigation which is composed of multiple questions detailed below. It is to the benefit of 
policymakers to be objective in their decision of whether or not they meet minimum criteria. While 
answering "No" to the questions below may not necessarily rule out a policy process aiming at 
support a biotechnology sector, it would mean that missing Sector Drivers will have to be accounted 
for in the strategy. 
Precondition for a Targeted Policy 
 
Is there a political commitment? (YES/NO) 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
Guiding questions: 
 
o Is the political commitment shared by multiple stakeholders? 
o What is the size of the group willing to pursue a targeted policy? 
o If it is a small group, how is it able to operate successfully without broader 
support? 
 
If the answer is "NO":  
If there is no political commitment, is 
there sufficient private sector support to 
move a TARGET strategy forward any 
way? 
 
If the answer is "YES":  
Since political commitment is usually 
tentative and may not be long-term, how 
would this affect the resources needed 
for a long-term strategy, and is it realistic 
to assume that a TARGET approach will 
be adhered to beyond a few years? 
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The Science Driver 
 
Does a strong science base exist? (YES/NO) 
 
 
 
 
 
  
Guiding questions:  
o Is the science base strong in a particular niche or overall? 
o Is the strength based on large size or just good performance from a small but 
qualified group? 
o What criteria are being used to judge this (e.g. internationally competitive 
for funding and in high impact journals; patent applications)? 
o How is R&D divided between basic research and applied research and is 
there high quality for each category?  
 
 
If the answer is "NO":  
Is the particular sector worth pursuing 
through a targeted approach or are there 
better candidate industries? 
 
 
If the answer is "YES":  
What are the possibilities of 
strengthening the science base in the 
short-term to achieve acceptable pre-
conditions for the industry? 
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The Training Driver 
 
Is a training personnel program already exist or required? (YES/NO)  
 
 
 
 
 
 
 
 
 
  
Guiding questions:  
o Are there sufficient knowledgeable investors, researchers and managers for 
the range of activity needed for a functioning innovation system?  
o What skills are missing? 
o Which kind of programs or training can be implemented? (Keeping in mind 
a time lag between the start of the programs and the first qualified 
individuals emerging). 
o Are there key individuals who can take on mentorship roles or be examples 
to others? 
 
 
 
 
 
If the answer is "YES":  
What are the possibilities of 
creating/strengthening a training 
program in the short-term to achieve 
acceptable pre-conditions for the 
industry? 
 
 
If the answer is "NO":  
Is the particular sector worth pursuing 
through a targeted approach or are there 
better candidate industries? 
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The Commercial Driver 
 
Is there a strong commercial basis for a targeted policy? (YES/NO)  
 
 
 
 
 
 
 
 
  
Guiding questions:  
o What is the measure of business activity in the sector? 
o What is the number of companies? 
o What indicators exist for judging commercial excellence and success in 
industry?  
o Are technically skilled people in the science base willing to work 
commercially or interact with commercial interests?  
o Are commercial skills set in other local industries are transferable?  
o What networks and existing contacts already exist?  
o Does the economy have any internationally recognized firms? Any local 
multinationals? 
o Is there foreign MNEs acting in the industry? What activities do they pursue 
locally? Are the activities high value-added or are they routine 
manufacturing/back-office work? 
 
If the answer is "YES":  
What are the possibilities of 
strengthening the commercial base in the 
short-term to achieve acceptable pre-
conditions for the industry? 
 
If the answer is "NO":  
Is the particular sector worth pursuing 
through a targeted approach or are there 
better candidate industries? 
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The Financial Driver 
 
Is there capacity for long run, significant financial support? (YES/NO) 
 
  
 
 
 
 
 
  
Guiding questions:  
o Is there any public financial policy to support life science/biomed activities? 
o How much funds are dedicated to life science/biomed projects as percentage 
of the public R&D budget? 
o Is there public investment on life science/biomed research centers? 
o Are there public investments on life science/biomed incubators? 
o Are there any public Venture Capital funds committed to life 
science/biomed? 
o Do public Venture Capital funds have a special focus on any particular life 
science/biomed area?  
o Are there any Public-Private Equity funds committed to life science/biomed? 
o Are there tax incentives for Venture Capital firms with special focus on life 
science/biomed sector?  
o Is there any specific incentive for the creation of life science/biomed focused 
Venture Capital firms? 
o How many companies specialized in Finance Consulting exist? 
 
 
 
If the answer is "YES":  
What are the possibilities of 
strengthening the financial base in the 
short-term to achieve acceptable pre-
conditions for the industry? 
 
If the answer is "NO":  
Is the particular sector worth pursuing 
through a targeted approach or are there 
better candidate industries? 
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The Human resources Driver  
 
Is there human resources availability? (YES/NO) 
 
 
 
 
 
 
 
 
 
 
  
Guiding questions:  
o Are there sufficient knowledgeable investors, researchers and managers for 
the range of activity needed for a functioning innovation system?  
o Is there at least a small number of outstanding individuals in the economy? 
o Do these individuals work as ‚Knowledge Brokers‛ / ‚Deal Makers‛? 
o Do they network internationally or only locally? 
o Are they active in managing firms, or also active working with or in other 
bodies? 
o Are they ideologically committed to developing the industry or sector? 
o Does the regulation enable the job mobility for Human Resources in Life 
science/biomed? 
 
 
 
 
If the answer is "YES":  
What are the possibilities of 
strengthening the human resource of the 
sector in the short-term to achieve 
acceptable pre-conditions for the 
industry? 
If the answer is "NO":  
Is the particular sector worth pursuing 
through a targeted approach or are there 
better candidate industries? 
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The 'Other Institution' Driver  
 
Do other institutions exist in the economy for facilitating a biotechnology sector? 
(YES/NO) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Guiding questions:  
o Is there a clear IP protection regime? 
o Is there clear legislation concerning clinical testing and product regulation? 
o Have actions been implemented to increase patent applications in Life 
science/biomed? 
o Have actions been implemented to increase university patent applications in 
Life science/biomed? 
o Are there workers at the Technology Transfer Offices (TTO) with specific 
knowledge for life science/biomed? 
o What is the health system budget as a percentage of the GDP? 
o What is the number of medical doctors in Clinical Hospitals? 
o How many people are working on clinical trial activities? 
o What is the annual number of clinical trials? 
o What is the annual number of clinical trials in starting phases? 
o Is there any specific action to promote public procurement on personalized 
medicine? 
o Are there actions to encourage the social acceptance regarding to life 
science/biomed innovations? 
 
 
 
If the answer is "YES":  
What are the possible measures in the 
short-term to achieve acceptable pre-
conditions for the industry? 
If the answer is "NO":  
Is the particular sector worth pursuing 
through a targeted approach or are there 
better candidate industries? 
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Examples of cases where agreement was relatively 
wide spread occurred in Ireland, Sweden and North 
Carolina. The agreement in these three cases to 
pursue an innovation strategy which included 
biotechnology as a key sector was held relatively 
widely because there was a perception of economic 
crisis in each case. This perception of crisis meant 
that, despite possible different interest and motivation 
sets amongst stakeholders, there was a common 
denominator to their interest set (overlapping 
interest) which meant that they collectively 
prioritized dealing with the economic crisis by 
supporting measures to foster innovation. 
Understanding this phenomenon goes beyond 
standard economic rationality assumptions for actors, 
and being able to do so would help policymakers and 
innovation policy leaders to create consensus outside 
of a crisis scenario.  
 
Annex 2: Stakeholder Cooperation 
As discussed above, while the kick-off decision does not necessarily have to be made by the party 
that will eventually manage the process, it is important that as wide an agreement as possible 
amongst stakeholders to pursue the strategy is obtained. For policymakers involved, this will involve 
different steps. The first is the identification of potential partners and/or opponents to such an 
approach. This is not to be confused with the later, more detailed identification of direct and indirect 
stakeholders who will be participating in the system which occurs simultaneously to the system 
assessment. Rather, this can be described as an identification of the triangle of public sector 
organizations that may be involved or whose interests overlap (different ministries or agencies), 
private sector organizations or firms (such as industry bodies, manufacturing concerns, key 
entrepreneurs or chambers of commerce) and universities. This may also include labour 
organizations if there is a large industrial presence in the context of the targeted sector in case 
proposed policies overlap or conflict with their interests.  
Briefly, according to political science 
theories of rationality, as well as 
organizational theory, different 
organizations have bounded rationalities 
which are determined by their own 
organizations history, learning capacity 
and environment. Individuals within one 
organization, while still rational, will not 
share the exact same concerns and values 
as individuals within another – these 
differences occur between firms in a field, 
and would be even more different between 
organizations such as a government 
ministry and a private firm. To individuals 
within these organizations, variables such 
as power, prestige, budget for activity, and 
profits will weigh, differently. For example, 
a business may consider a cut in 
operational budget as perfectly acceptable 
so long as an increase in profit follows; to a direct in a government department, a loss in budget will 
likely motivate them to oppose particular measures since profit does not enter into their personal 
gain, and in fact may be tied in to a loss in personal and departmental prestige. Operationally, 
therefore, a simple understanding of the different motivations of stakeholders is necessary to 
understand how different interests may be co-opted, or if that is not possible, overcome. 
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Furthermore, the canvassing of potential partners for kicking off a targeted approach should be done 
as early as possible. 
Besides these individual interests of different organizations, the different stages of a sector's 
development will have different effects on the ability to obtain agreement for kick-off at the 
beginning of the process. While it is more risky or entrepreneurial to kick off a targeted approach at 
an earlier stage of evolution, there will likely be more parties and interests at later stages with 
potentially more entrenched interests, which may lead to greater complications. With the stage of 
development in mind, it should be noted that in the cases discussed, it was mostly support for 
innovative sectors, not just biotechnology – in some cases biotechnology was not really a strength but 
a desire – perhaps not ideal to pursue. If so, how much willing is there to invest? 
Also, in terms of operationalizing the kick-off agreement, what is the minimal achievement? What is 
the bare minimum ideal for coordination? It may be suggested that if a sufficient majority in any area 
can agree then this is enough agreement for at least three years initial budget commitment. 
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The TARGET approach presented here 
will help policymakers form a strategic 
roadmap and determine feasible 
interventions that lead to a functioning 
biotechnology system of innovation 
within a country or region. The goal of 
the Toolkit is not to present a single 
recipe of specific policies for success; as 
will be noted later on, the variety of cases 
and their development mean that no 
single path to a functionally 
biotechnology sector can be realistically 
described. 
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